

# CPC COOPERATIVE PATENT CLASSIFICATION

## C CHEMISTRY; METALLURGY

(NOTES omitted)

### CHEMISTRY

#### C12 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLGY; MUTATION OR GENETIC ENGINEERING

(NOTES omitted)

#### C12N MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ([microbiological testing media C12Q 1/00](#))

##### NOTES

1. Attention is drawn to Notes (1) to (3) following the title of class [C12](#).
2. Biocidal, pest repellent, pest attractant or plant growth regulatory activity of compounds or preparations is further classified in subclass [A01P](#).
3. Therapeutic activity of single-cell proteins or enzymes is further classified in subclass [A61P](#).
4. When classifying in this subclass, classification is also made in group [B01D 15/08](#) insofar as subject matter of general interest relating to chromatography is concerned.
5. In this subclass, it is desirable to add the indexing codes of subclass [C12R](#).
6. {Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes.}
7. {In this subclass, combination sets [C-Sets] are used. The detailed information about the C-Sets construction and the associated syntax rules is present in the definitions of [C12N](#).}

##### WARNINGS

1. The following IPC groups are not in the CPC scheme. The subject matter for these IPC groups is classified in the following CPC groups:

<a href="#">C12N 1/11</a>	covered by	<a href="#">C12N 15/79</a>
<a href="#">C12N 1/13</a>	covered by	<a href="#">C12N 15/79</a>
<a href="#">C12N 1/15</a>	covered by	<a href="#">C12N 15/80</a>
<a href="#">C12N 1/19</a>	covered by	<a href="#">C12N 15/81</a>
<a href="#">C12N 1/21</a>	covered by	<a href="#">C12N 15/74</a>
<a href="#">C12N 5/02</a>	covered by	<a href="#">C12N 5/0006</a> , <a href="#">C12N 5/04</a> - <a href="#">C12N 5/166</a>
<a href="#">C12N 5/07</a> - <a href="#">C12N 5/095</a>	covered by	<a href="#">C12N 5/06</a>
<a href="#">C12N 5/18</a>	covered by	<a href="#">C12N 5/16</a>
<a href="#">C12N 5/20</a>	covered by	<a href="#">C12N 5/163</a>
<a href="#">C12N 5/22</a>	covered by	<a href="#">C12N 5/16</a>
<a href="#">C12N 5/24</a>	covered by	<a href="#">C12N 5/163</a>
<a href="#">C12N 5/26</a>	covered by	<a href="#">C12N 5/166</a>
<a href="#">C12N 5/28</a>	covered by	<a href="#">C12N 5/166</a>
<a href="#">C12N 15/53</a>	covered by	<a href="#">C12N 9/0004</a>
<a href="#">C12N 7/01</a>	covered by	<a href="#">C12N 7/00</a>
<a href="#">C12N 9/02</a> - <a href="#">C12N 9/08</a>	covered by	<a href="#">C12N 9/0004</a>
<a href="#">C12N 9/26</a>	covered by	<a href="#">C12N 9/2408</a>
<a href="#">C12N 9/28</a> - <a href="#">C12N 9/30</a>	covered by	<a href="#">C12N 9/2414</a> - <a href="#">C12N 9/242</a>
<a href="#">C12N 9/32</a>	covered by	<a href="#">C12N 9/2422</a>
<a href="#">C12N 9/34</a>	covered by	<a href="#">C12N 9/2428</a>
<a href="#">C12N 9/36</a>	covered by	<a href="#">C12N 9/2462</a>
<a href="#">C12N 9/38</a>	covered by	<a href="#">C12N 9/2468</a>
<a href="#">C12N 9/40</a>	covered by	<a href="#">C12N 9/2465</a>
<a href="#">C12N 9/42</a>	covered by	<a href="#">C12N 9/2434</a>
<a href="#">C12N 9/44</a>	covered by	<a href="#">C12N 9/2451</a>
<a href="#">C12N 9/46</a>	covered by	<a href="#">C12N 9/2454</a>
<a href="#">C12N 9/56</a>	covered by	<a href="#">C12N 9/54</a>
<a href="#">C12N 9/66</a>	covered by	<a href="#">C12N 9/6448</a>
<a href="#">C12N 9/68</a>	covered by	<a href="#">C12N 9/6435</a>
<a href="#">C12N 9/70</a>	covered by	<a href="#">C07K 14/3153</a>
<a href="#">C12N 9/72</a>	covered by	<a href="#">C12N 9/6462</a>

C12N

C12N  
(continued)

C12N 9/74	covered by	<a href="#">C12N 9/6429</a>
C12N 9/76	covered by	<a href="#">C12N 9/6427</a>
C12N 15/05	covered by	<a href="#">C12N 5/14</a>
C12N 15/06	covered by	<a href="#">C12N 5/16</a>
C12N 15/07	covered by	<a href="#">C12N 5/16</a>
C12N 15/08	covered by	<a href="#">C12N 5/166</a>
C12N 15/12	covered by	<a href="#">C07K 14/435</a>
C12N 15/13	covered by	<a href="#">C07K 16/00</a>
C12N 15/14	covered by	<a href="#">C07K 14/765</a>
C12N 15/15	covered by	<a href="#">C07K 14/81</a>
C12N 15/16	covered by	<a href="#">C07K 14/575</a>
C12N 15/17	covered by	<a href="#">C07K 14/62</a>
C12N 15/18	covered by	<a href="#">C07K 14/61</a>
C12N 15/19	covered by	<a href="#">C07K 14/52</a>
C12N 15/20	covered by	<a href="#">C07K 14/555</a>
C12N 15/21	covered by	<a href="#">C07K 14/56</a>
C12N 15/22	covered by	<a href="#">C07K 14/565</a>
C12N 15/23	covered by	<a href="#">C07K 14/57</a>
C12N 15/24	covered by	<a href="#">C07K 14/54</a>
C12N 15/25	covered by	<a href="#">C07K 14/545</a>
C12N 15/26	covered by	<a href="#">C07K 14/55</a>
C12N 15/27	covered by	<a href="#">C07K 14/53</a>
C12N 15/28	covered by	<a href="#">C07K 14/525</a>
C12N 15/29	covered by	<a href="#">C07K 14/415</a>
C12N 15/30	covered by	<a href="#">C07K 14/44</a>
C12N 15/31	covered by	<a href="#">C07K 14/195</a> , <a href="#">C07K 14/005</a>
C12N 15/32	covered by	<a href="#">C07K 14/325</a>
C12N 15/33	covered by	<a href="#">C07K 14/005</a>
C12N 15/34	covered by	<a href="#">C07K 14/01</a>
C12N 15/35	covered by	<a href="#">C07K 14/015</a>
C12N 15/36	covered by	<a href="#">C07K 14/02</a>
C12N 15/37	covered by	<a href="#">C07K 14/025</a>
C12N 15/38	covered by	<a href="#">C07K 14/03</a>
C12N 15/39	covered by	<a href="#">C07K 14/065</a>
C12N 15/40	covered by	<a href="#">C07K 14/08</a>
C12N 15/41	covered by	<a href="#">C07K 14/085</a>
C12N 15/42	covered by	<a href="#">C07K 14/09</a>
C12N 15/43	covered by	<a href="#">C07K 14/105</a>
C12N 15/44	covered by	<a href="#">C07K 14/11</a>
C12N 15/45	covered by	<a href="#">C07K 14/115</a>
C12N 15/46	covered by	<a href="#">C07K 14/14</a>
C12N 15/47	covered by	<a href="#">C07K 14/145</a>
C12N 15/48	covered by	<a href="#">C07K 14/15</a>
C12N 15/49	covered by	<a href="#">C07K 14/155</a>
C12N 15/50	covered by	<a href="#">C07K 14/165</a>
C12N 15/51	covered by	<a href="#">C07K 14/02</a> , <a href="#">C07K 14/10</a> , <a href="#">C07K 14/18</a>
C12N 15/53	covered by	<a href="#">C12N 9/0004</a>
C12N 15/54	covered by	<a href="#">C12N 9/10</a>
C12N 15/55	covered by	<a href="#">C12N 9/14</a>
C12N 15/56	covered by	<a href="#">C12N 9/24</a>
C12N 15/57	covered by	<a href="#">C12N 9/48</a>
C12N 15/58	covered by	<a href="#">C12N 9/6456</a>
C12N 15/59	covered by	<a href="#">C12N 9/6483</a>
C12N 15/60	covered by	<a href="#">C12N 9/88</a>
C12N 15/61	covered by	<a href="#">C12N 9/90</a>
C12N 15/83	covered by	<a href="#">C12N 15/82</a>
C12N 15/84	covered by	<a href="#">C12N 15/82</a>

2. In this subclass non-limiting references (in the sense of paragraph 39 of the Guide to the IPC) may still be displayed in the scheme.

- 1/00 Microorganisms, e.g. protozoa; Compositions thereof** (medicinal preparations containing material from protozoa, bacteria or viruses [A61K 35/66](#), from algae [A61K 36/02](#), from fungi [A61K 36/06](#); preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines, [A61K 39/00](#)); **Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor**
- 1/005 . {after treatment of microbial biomass not covered by [C12N 1/02](#) - [C12N 1/08](#)}
- 1/02 . Separating microorganisms from their culture media
- 1/04 . Preserving or maintaining viable microorganisms (immobilised microorganisms [C12N 11/00](#))
- 1/06 . Lysis of microorganisms
- 1/063 . . {of yeast}
- 1/066 . . {by physical methods}
- 1/08 . Reducing the nucleic acid content
- 1/10 . Protozoa; Culture media therefor
- 1/105 . . {Protozoal isolates}
- 1/12 . Unicellular algae; Culture media therefor (as new plants [A01H 13/00](#))
- 1/125 . . {Unicellular algae isolates}
- 1/14 . Fungi (culture of mushrooms [A01G 18/00](#); as new plants [A01H 15/00](#)); Culture media therefor
- 1/145 . . {Fungal isolates}
- 1/16 . . Yeasts; Culture media therefor
- 1/165 . . . {Yeast isolates}
- 1/18 . . . Baker's yeast; Brewer's yeast
- 1/185 . . . . {Saccharomyces isolates}
- 1/20 . Bacteria; Culture media therefor
- 1/205 . . {Bacterial isolates}
- 1/22 . Processes using, or culture media containing, cellulose or hydrolysates thereof
- 1/24 . Processes using, or culture media containing, waste sulfite liquor
- 1/26 . Processes using, or culture media containing, hydrocarbons (refining of hydrocarbon oils by using microorganisms [C10G 32/00](#))
- 1/28 . . aliphatic
- 1/30 . . . having five or less carbon atoms
- 1/32 . Processes using, or culture media containing, lower alkanols, i.e. C<sub>1</sub> to C<sub>6</sub>
- 1/34 . Processes using foam culture
- 1/36 . Adaptation or attenuation of cells
- 1/38 . Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound ([C12N 1/34](#) takes precedence)
- 3/00 Spore forming or isolating processes**
- 5/00 Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor;** (plant reproduction by tissue culture techniques [A01H 4/00](#))
- NOTE**
- In this group, the following words are used with the meanings indicated:
- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
  - a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
  - a "multipotent" cell is restricted to one lineage. }
- "Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny.
- 5/0006 . {Modification of the membrane of cells, e.g. cell decoration}
- 5/0012 . {Cell encapsulation}
- 5/0018 . {Culture media for cell or tissue culture (media for specific animal cell type [C12N 5/06](#))}
- 5/0025 . . {Culture media for plant cell or plant tissue culture}
- 5/0031 . . {Serum-free culture media}
- WARNING**
- This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to [C12N 5/0037](#) - [C12N 5/0056](#)
- 5/0037 . . {Serum-free medium, which may still contain naturally-sourced components}
- 5/0043 . . {Medium free of human- or animal-derived components}
- 5/005 . . {Protein-free medium}
- 5/0056 . . {Xeno-free medium}
- 5/0062 . {General methods for three-dimensional culture}
- 5/0068 . {General culture methods using substrates (for specific animal cell type [C12N 5/06](#))}
- 5/0075 . . {using microcarriers}
- 5/0081 . {Purging biological preparations of unwanted cells}
- 5/0087 . . {Purging against subsets of blood cells, e.g. purging alloreactive T cells}
- 5/0093 . . {Purging against cancer cells}
- 5/04 . Plant cells or tissues {(culture media [C12N 5/0025](#))}
- 5/06 . {Animal cells or tissues; Human cells or tissues (preservation of living cells or tissues [A01N 1/02](#))}
- NOTE**
- {In this group, the following words are used with the meanings indicated:
- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
  - a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
  - a "multipotent" cell is restricted to one lineage. }
- "Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with

C12N

C12N 5/06  
(continued)

- pluripotent cells. Multipotent cells should not be classified with pluripotent cells. The last place priority rule does not apply between the subgroups of this group
- 5/0601 . . {Invertebrate cells or tissues, e.g. insect cells; Culture media therefor}
- 5/0602 . . {Vertebrate cells}
- NOTE**  
Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for
- 5/0603 . . . {Embryonic cells (production of embryos, nuclear transfer [A01K 67/027](#)); Embryoid bodies}
- 5/0604 . . . . {Whole embryos; Culture medium therefor}
- 5/0605 . . . . {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- 5/0606 . . . . {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells [C12N 5/0611](#), induced pluripotent stem cells [C12N 5/0696](#))}
- 5/0607 . . . {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells [C12N 5/0696](#))}
- 5/0608 . . . {Germ cells (production of embryos, nuclear transfer [A01K 67/027](#))}
- 5/0609 . . . . {Oocytes, oogonia (fertilised oocytes [C12N 5/0604](#))}
- 5/061 . . . . {Sperm cells, spermatogonia}
- 5/0611 . . . . {Primordial germ cells, e.g. embryonic germ cells [EG]}
- 5/0612 . . . . {sorting of gametes, e.g. according to sex or motility}
- 5/0613 . . . {Cells from endocrine organs ([pancreas C12N 5/0676](#), [gonads C12N 5/0681](#))}
- 5/0614 . . . . {Adrenal gland}
- 5/0615 . . . . {Pineal gland}
- 5/0616 . . . . {Pituitary gland}
- 5/0617 . . . . {Thyroid and parathyroid glands}
- 5/0618 . . . {Cells of the nervous system}
- 5/0619 . . . . {Neurons}
- 5/062 . . . . {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}
- 5/0621 . . . . {Eye cells, e.g. cornea, iris pigmented cells ([photoreceptors C12N 5/062](#))}
- 5/0622 . . . . {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- 5/0623 . . . . {Stem cells}
- 5/0625 . . . {Epidermal cells, skin cells; Cells of the oral mucosa}
- 5/0626 . . . . {Melanocytes}
- 5/0627 . . . . {Hair cells}
- 5/0628 . . . . {Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles [C12N 5/0666](#))}
- 5/0629 . . . . {Keratinocytes; Whole skin}
- 5/063 . . . . {Keratinocyte stem cells; Keratinocyte progenitors}
- 5/0631 . . . . {Mammary cells}
- 5/0632 . . . . {Cells of the oral mucosa}
- 5/0633 . . . . {Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands}
- 5/0634 . . . {Cells from the blood or the immune system}
- NOTE**  
Committed progenitors are classified with their progeny
- 5/0635 . . . . {B lymphocytes}
- 5/0636 . . . . {T lymphocytes}
- 5/0637 . . . . {Immunosuppressive T lymphocytes, e.g. regulatory T cells (Treg)}
- 5/0638 . . . . . {Cytotoxic T lymphocytes [CTL], lymphokine activated killer cells [LAK]}
- 5/0639 . . . . {Dendritic cells, e.g. Langerhans cells in the epidermis}
- 5/064 . . . . . {Immunosuppressive dendritic cells}
- 5/0641 . . . . {Erythrocytes}
- 5/0642 . . . . {Granulocytes, e.g. basophils, eosinophils, neutrophils, mast cells}
- 5/0643 . . . . {Osteoclasts}
- 5/0644 . . . . {Platelets; Megakaryocytes}
- 5/0645 . . . . {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}
- 5/0646 . . . . {Natural killers cells [NK], NKT cells}
- 5/0647 . . . . {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- 5/0648 . . . . {Splenocytes}
- 5/065 . . . . {Thymocytes}
- 5/0651 . . . . {Lymph nodes}
- 5/0652 . . . {Cells of skeletal and connective tissues; Mesenchyme}
- 5/0653 . . . . {Adipocytes; Adipose tissue}
- 5/0654 . . . . {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}
- 5/0655 . . . . {Chondrocytes; Cartilage}
- 5/0656 . . . . {Adult fibroblasts}
- 5/0657 . . . . {Cardiomyocytes; Heart cells}
- 5/0658 . . . . {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}
- 5/0659 . . . . . {Satellite cells}
- 5/066 . . . . {Tenocytes; Tendons, Ligaments}
- 5/0661 . . . . {Smooth muscle cells}
- 5/0662 . . . . {Stem cells}
- 5/0663 . . . . . {Bone marrow mesenchymal stem cells (BM-MSC)}
- 5/0664 . . . . . {Dental pulp stem cells, Dental follicle stem cells}
- 5/0665 . . . . . {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}
- 5/0666 . . . . . {Mesenchymal stem cells from hair follicles}
- 5/0667 . . . . . {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- 5/0668 . . . . . {Mesenchymal stem cells from other natural sources}
- 5/0669 . . . . {Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow [C12N 5/0647](#), [C12N 5/0663](#))}
- 5/067 . . . {Hepatocytes}
- 5/0671 . . . . {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}

- 5/0672 . . . . {Stem cells; Progenitor cells; Precursor cells; Oval cells}
- 5/0676 . . . {Pancreatic cells}
- 5/0677 . . . . {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
- 5/0678 . . . . {Stem cells; Progenitor cells; Precursor cells}
- 5/0679 . . . {Cells of the gastro-intestinal tract}
- 5/068 . . . . {Stem cells; Progenitors}
- 5/0681 . . . {Cells of the genital tract; Non-germinal cells from gonads}
- 5/0682 . . . . {Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells ([oocytes C12N 5/0609](#))}
- 5/0683 . . . . {Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells ([spermatogonia C12N 5/061](#))}
- 5/0684 . . . {Cells of the urinary tract or kidneys}
- 5/0685 . . . . {Bladder epithelial cells}
- 5/0686 . . . . {Kidney cells}
- 5/0687 . . . . {Renal stem cells; Renal progenitors}
- 5/0688 . . . {Cells from the lungs or the respiratory tract}
- 5/0689 . . . . {Stem cells; Progenitors}
- 5/069 . . . {Vascular Endothelial cells}
- 5/0691 . . . . {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}
- 5/0692 . . . . {Stem cells; Progenitor cells; Precursor cells}
- 5/0693 . . . {Tumour cells; Cancer cells}
- 5/0694 . . . . {Cells of blood, e.g. leukemia cells, myeloma cells}
- 5/0695 . . . . {Stem cells; Progenitor cells; Precursor cells}
- 5/0696 . . . {Artificially induced pluripotent stem cells, e.g. iPS}
- 5/0697 . . {Artificial constructs associating cells of different lineages, e.g. tissue equivalents ([blood vessels C12N 5/0691](#))}
- 5/0698 . . . {Skin equivalents}
- 5/10 . Cells modified by introduction of foreign genetic material
- 5/12 . . Fused cells, e.g. hybridomas
- 5/14 . . . Plant cells
- 5/16 . . . Animal cells
- 5/163 . . . . {one of the fusion partners being a B or a T lymphocyte}
- 5/166 . . . . {resulting from interspecies fusion}
- 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, [A61K 39/00](#))**
- WARNING**
- From March 15, 2012 groups [C12N 7/02](#) - [C12N 7/08](#) and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range [C12N 2710/00-C12N 2795/00](#).
- 7/02 . Recovery or purification
- 7/025 . . {Packaging cell lines, e.g. transcomplementing cell lines, for production of virus}
- 7/04 . Inactivation or attenuation; Producing viral sub-units
- 7/045 . . {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered}
- 7/06 . . {Inactivation or attenuation} by chemical treatment
- 7/08 . . {Inactivation or attenuation} by serial passage of virus
- 9/00 Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth [A61K 8/66](#), [A61Q 11/00](#); medicinal preparations containing enzymes or proenzymes [A61K 38/43](#); enzyme containing detergent compositions [C11D](#); {enzymes with nucleic acid structure, e.g. ribozymes, [C12N 15/113](#)}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt [C12C 1/00](#))**
- NOTE**
- Enzymes are generally categorized below according to the "Nomenclature and Classification of Enzymes" of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.
- 9/0002 . {Antibodies with enzymatic activity, e.g. abzymes}
- 9/0004 . {Oxidoreductases (1.)}
- 9/0006 . . {acting on CH-OH groups as donors (1.1)}
- 9/0008 . . {acting on the aldehyde or oxo group of donors (1.2)}
- 9/001 . . {acting on the CH-CH group of donors (1.3)}
- 9/0012 . . {acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)}
- 9/0014 . . . {acting on the CH-NH<sub>2</sub> group of donors (1.4)}
- 9/0016 . . . . {with NAD or NADP as acceptor (1.4.1)}
- 9/0018 . . . . {Phenylalanine dehydrogenase (1.4.1.20)}
- 9/002 . . . . {with a cytochrome as acceptor (1.4.2)}
- 9/0022 . . . . {with oxygen as acceptor (1.4.3)}
- 9/0024 . . . . {D-Amino acid oxidase (1.4.3.3)}
- 9/0026 . . . {acting on CH-NH groups of donors (1.5)}
- 9/0028 . . . . {with NAD or NADP as acceptor (1.5.1)}
- 9/003 . . . . {Dihydrofolate reductase [DHFR] (1.5.1.3)}
- 9/0032 . . . . {with oxygen as acceptor (1.5.3)}
- 9/0034 . . . . {Sarcosine oxidase (1.5.3.1)}
- 9/0036 . . . {acting on NADH or NADPH (1.6)}
- 9/0038 . . . . {with a heme protein as acceptor (1.6.2)}
- 9/004 . . . . {Cytochrome-b5 reductase (1.6.2.2)}
- 9/0042 . . . . {NADPH-cytochrome P450 reductase (1.6.2.4)}
- 9/0044 . . . {acting on other nitrogen compounds as donors (1.7)}
- 9/0046 . . . . {with oxygen as acceptor (1.7.3)}
- 9/0048 . . . . {Uricase (1.7.3.3)}
- 9/0051 . . {acting on a sulfur group of donors (1.8)}
- 9/0053 . . {acting on a heme group of donors (1.9)}
- 9/0055 . . {acting on diphenols and related substances as donors (1.10)}
- 9/0057 . . . {with oxygen as acceptor (1.10.3)}
- 9/0059 . . . . {Catechol oxidase (1.10.3.1), i.e. tyrosinase}
- 9/0061 . . . . {Laccase (1.10.3.2)}

- 9/0063 . . . . {Ascorbate oxidase (1.10.3.3)}
- 9/0065 . . {acting on hydrogen peroxide as acceptor (1.11)}
- 9/0067 . . {acting on hydrogen as donor (1.12)}
- 9/0069 . . {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}
- 9/0071 . . {acting on paired donors with incorporation of molecular oxygen (1.14)}
- 9/0073 . . . {with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13}
- 9/0075 . . . . {Nitric-oxide synthase (1.14.13.39)}
- 9/0077 . . . {with a reduced iron-sulfur protein as one donor (1.14.15)}
- 9/0079 . . . . {Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)}
- 9/0081 . . . . {Cholesterol monooxygenase (cytochrome P 450sc)(1.14.15.6)}
- 9/0083 . . . {Miscellaneous (1.14.99)}
- 9/0085 . . . . {Steroid 17 alpha-monooxygenase (1.14.99.9)}
- 9/0087 . . . . {Steroid 21-monooxygenase (1.14.99.10)}
- 9/0089 . . {acting on superoxide as acceptor (1.15)}
- 9/0091 . . {oxidizing metal ions (1.16)}
- 9/0093 . . {acting on CH or CH<sub>2</sub> groups (1.17)}
- 9/0095 . . {acting on iron-sulfur proteins as donor (1.18)}
- 9/0097 . . {acting on reduced flavodoxin as donor (1.19)}
- 9/10 . . . . **Transferases (2.) (ribonucleases [C12N 9/22](#))**
- 9/1003 . . {transferring one-carbon groups (2.1)}
- 9/1007 . . . {Methyltransferases (general) (2.1.1.)}
- 9/1011 . . . . {Catechol O-methyltransferase (2.1.1.6)}
- 9/1014 . . . . {Hydroxymethyl-, formyl-transferases (2.1.2.)}
- 9/1018 . . . . {Carboxy- and carbamoyl transferases (2.1.3.)}
- 9/1022 . . {transferring aldehyde or ketonic groups (2.2.)}
- 9/1025 . . {Acytransferases (2.3.)}
- 9/1029 . . . {transferring groups other than amino-acyl groups (2.3.1.)}
- 9/1033 . . . . {Chloramphenicol O-acetyltransferase (2.3.1.28)}
- 9/1037 . . . . {Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase}
- 9/104 . . . {Aminoacyltransferases (2.3.2.)}
- 9/1044 . . . . {Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII}
- 9/1048 . . {Glycosyltransferases (2.4.)}
- 9/1051 . . . {Hexosyltransferases (2.4.1.)}
- 9/1055 . . . . {Levansucrase (2.4.1.10)}
- 9/1059 . . . . {Cellulose synthases (2.4.1.12; 2.4.1.29)}
- 9/1062 . . . . {Sucrose synthase (2.4.1.13)}
- 9/1066 . . . . {Sucrose phosphate synthase (2.4.1.14)}
- 9/107 . . . . {1,4-Alpha-glucan branching enzyme (2.4.1.18)}
- 9/1074 . . . . {Cyclomaltodextrin glucanotransferase (2.4.1.19)}
- 9/1077 . . . {Pentosyltransferases (2.4.2.)}
- 9/1081 . . . {transferring other glycosyl groups (2.4.99)}
- 9/1085 . . {transferring alkyl or aryl groups other than methyl groups (2.5.)}
- 9/1088 . . . {Glutathione transferase (2.5.1.18)}
- 9/1092 . . . {3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase}
- 9/1096 . . {transferring nitrogenous groups (2.6.)}
- 9/12 . . . transferring phosphorus containing groups, e.g. kinases (2.7)
- 9/1205 . . . {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- 9/1211 . . . . {Thymidine kinase (2.7.1.21)}
- 9/1217 . . . {Phosphotransferases with a carboxyl group as acceptor (2.7.2.)}
- 9/1223 . . . {Phosphotransferases with a nitrogenous group as acceptor (2.7.3.)}
- 9/1229 . . . {Phosphotransferases with a phosphate group as acceptor (2.7.4.)}
- 9/1235 . . . {Diphosphotransferases (2.7.6.)}
- 9/1241 . . . {Nucleotidyltransferases (2.7.7.)}
- 9/1247 . . . . {DNA-directed RNA polymerase (2.7.7.6.)}
- 9/1252 . . . . {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}
- 9/1258 . . . . {Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase}
- 9/1264 . . . . {DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase}
- 9/127 . . . . {RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase}
- 9/1276 . . . . {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- 9/1282 . . . . {RNA uridylyltransferase (2.7.7.52.)}
- 9/1288 . . . {Transferases for other substituted phosphate groups (2.7.8.)}
- 9/1294 . . . {Phosphotransferases with paired acceptors (2.7.9.)}
- 9/13 . . {transferring sulfur containing groups (2.8.)}
- 9/14 . . . **Hydrolases (3)**
- 9/16 . . . acting on ester bonds (3.1)
- 9/18 . . . . Carboxylic ester hydrolases {(3.1.1.)}
- 9/20 . . . . Triglyceride splitting, e.g. by means of lipase
- 9/22 . . . **Ribonucleases {RNAses, DNAses ([catalytic nucleic acids C12N 15/113](#))}**
- 9/24 . . . acting on glycosyl compounds (3.2)
- 9/2402 . . . {hydrolysing O- and S- glycosyl compounds (3.2.1.)}
- 9/2405 . . . . {Glucanases}
- 9/2408 . . . . . {acting on alpha -1,4-glucosidic bonds}
- 9/2411 . . . . . {Amylases}
- 9/2414 . . . . . . {Alpha-amylase (3.2.1.1.)}
- 9/2417 . . . . . . . {from microbiological source}
- 9/242 . . . . . . . {Fungal source}
- 9/2422 . . . . . . . {from plant source}
- 9/2425 . . . . . . . {Beta-amylase (3.2.1.2.)}
- 9/2428 . . . . . . . {Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase}
- 9/2431 . . . . . . . {Beta-fructofuranosidase (3.2.1.26), i.e. invertase}
- 9/2434 . . . . . . . {acting on beta-1,4-glucosidic bonds}
- 9/2437 . . . . . . . {Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)}
- 9/244 . . . . . . . {Endo-1,3(4)-beta-glucanase (3.2.1.6.)}
- 9/2442 . . . . . . . {Chitinase (3.2.1.14.)}
- 9/2445 . . . . . . . {Beta-glucosidase (3.2.1.21.)}
- 9/2448 . . . . . . . {Licheninase (3.2.1.73.)}
- 9/2451 . . . . . . . {acting on alpha-1,6-glucosidic bonds}
- 9/2454 . . . . . . . {Dextranase (3.2.1.11.)}
- 9/2457 . . . . . . . {Pullulanase (3.2.1.41.)}
- 9/246 . . . . . . . {Isoamylase (3.2.1.68.)}
- 9/2462 . . . . . . . {Lysozyme (3.2.1.17.)}

9/2465	. . . . {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}	9/6454	. . . . . {Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases}
9/2468	. . . . {acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)}	9/6456	. . . . . {Plasminogen activators}
9/2471	. . . . . {Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase}	9/6459	. . . . . {t-plasminogen activator (3.4.21.68), i.e. tPA}
9/2474	. . . . {Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase}	9/6462	. . . . . {u-Plasminogen activator (3.4.21.73), i.e. urokinase}
9/2477	. . . . {Hemicellulases not provided in a preceding group}	9/6464	. . . . . {Protein C (3.4.21.69)}
9/248	. . . . . {Xylanases}	9/6467	. . . . . {Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)}
9/2482	. . . . . {Endo-1,4-beta-xylanase (3.2.1.8)}	9/647	. . . . . {Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups}
9/2485	. . . . . {Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase}	9/6472	. . . . . {Cysteine endopeptidases (3.4.22)}
9/2488	. . . . . {Mannanases}	9/6475	. . . . . {Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)}
9/2491	. . . . . {Beta-mannosidase (3.2.1.25), i.e. mannanase}	9/6478	. . . . . {Aspartic endopeptidases (3.4.23)}
9/2494	. . . . . {Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase}	9/6481	. . . . . {Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)}
9/2497	. . . {hydrolysing N- glycosyl compounds (3.2.2)}	9/6483	. . . . . {Chymosin (3.4.23.4), i.e. rennin}
9/48	. . acting on peptide bonds (3.4)	9/6486	. . . . . {Renin (3.4.23.15)}
9/485	. . . {Exopeptidases (3.4.11-3.4.19)}	9/6489	. . . . . {Metalloendopeptidases (3.4.24)}
9/50	. . . Proteinases {, e.g. Endopeptidases (3.4.21-3.4.25)}	9/6491	. . . . . {Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)}
9/503	. . . . {derived from viruses}	9/6494	. . . . . {Nepriylsin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11}
9/506	. . . . . {derived from RNA viruses}	9/6497	. . . . . {Endothelin-converting enzyme (3.4.24.71)}
9/52	. . . . derived from bacteria {or Archaea}	9/78	. . acting on carbon to nitrogen bonds other than peptide bonds (3.5)
<b>NOTE</b>		9/80	. . . acting on amide bonds in linear amides {(3.5.1)}
{In this group, Archaea, formerly known as Archaeobacteria, are classified with bacteria.}		9/82	. . . . Asparaginase {(3.5.1.1)}
9/54	. . . . . bacteria being Bacillus	9/84	. . . . Penicillin amidase {(3.5.1.11)}
9/58	. . . . . derived from fungi	9/86	. . . acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)}
9/60	. . . . . from yeast	9/88	. Lyases (4.)
9/62	. . . . . from Aspergillus	9/90	. Isomerases (5.)
9/63	. . . . . {derived from plants}	9/92	. . Glucose isomerase {(5.3.1.5; 5.3.1.9; 5.3.1.18)}
9/64	. . . . . derived from animal tissue	9/93	. {Ligases (6)}
9/6402	. . . . . {from non-mammals}	9/94	. Pancreatin
9/6405	. . . . . {not being snakes}	9/96	. Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
9/6408	. . . . . {Serine endopeptidases (3.4.21)}	9/98	. Preparation of granular or free-flowing enzyme compositions ( <a href="#">C12N 9/96 takes precedence</a> )
9/641	. . . . . {Cysteine endopeptidases (3.4.22)}	9/99	. Enzyme inactivation by chemical treatment
9/6413	. . . . . {Aspartic endopeptidases (3.4.23)}	<b>11/00</b>	<b>Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof</b>
9/6416	. . . . . {Metalloendopeptidases (3.4.24)}	11/02	. Enzymes or microbial cells immobilised on or in an organic carrier
9/6418	. . . . . {from snakes}	11/04	. . entrapped within the carrier, e.g. gel or hollow fibres
9/6421	. . . . . {from mammals}	11/06	. . attached to the carrier via a bridging agent
9/6424	. . . . . {Serine endopeptidases (3.4.21)}	11/08	. . the carrier being a synthetic polymer
9/6427	. . . . . {Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)}		
9/6429	. . . . . {Thrombin (3.4.21.5)}		
9/6432	. . . . . {Coagulation factor Xa (3.4.21.6)}		
9/6435	. . . . . {Plasmin (3.4.21.7), i.e. fibrinolysin}		
9/6437	. . . . . {Coagulation factor VIIa (3.4.21.21)}		
9/644	. . . . . {Coagulation factor IXa (3.4.21.22)}		
9/6443	. . . . . {Coagulation factor XIa (3.4.21.27)}		
9/6445	. . . . . {Kallikreins (3.4.21.34; 3.4.21.35)}		
9/6448	. . . . . {Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)}		
9/6451	. . . . . {Coagulation factor XIIIa (3.4.21.38)}		

- 11/082 . . . obtained by reactions only involving carbon-to-carbon unsaturated bonds
- 11/084 . . . . Polymers containing vinyl alcohol units
- 11/087 . . . . Acrylic polymers
- 11/089 . . . obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- 11/091 . . . . Phenol resins; Amino resins
- 11/093 . . . . Polyurethanes
- 11/096 . . . . Polyesters; Polyamides
- 11/098 . . . formed in the presence of the enzymes or microbial cells
- 11/10 . . the carrier being a carbohydrate
- 11/12 . . . Cellulose or derivatives thereof
- 11/14 . Enzymes or microbial cells immobilised on or in an inorganic carrier
- 11/16 . Enzymes or microbial cells immobilised on or in a biological cell
- 11/18 . Multi-enzyme systems
- 13/00 Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves**
- 15/00 Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se [C12N 1/00](#), [C12N 5/00](#), [C12N 7/00](#); new plants per se [A01H](#); plant reproduction by tissue culture techniques [A01H 4/00](#); new animals per se [A01K 67/00](#); use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy [A61K 48/00](#))**
- 15/01 . Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
- 15/02 . Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies [C07K 16/00](#); apparatus for cell fusion [C12M](#))}
- 15/03 . . Bacteria
- 15/04 . . Fungi
- 15/09 . Recombinant DNA-technology
- 15/10 . . Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA [C07H 21/00](#); preparation of non-structural polynucleotides from microorganisms or with enzymes [C12P 19/34](#))
- NOTE**
- {In groups [C12N 15/10](#) - [C12N 15/1096](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}.
- 15/1003 . . . {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- 15/1006 . . . . {by means of a solid support carrier, e.g. particles, polymers}
- 15/101 . . . . . {by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}
- 15/1013 . . . . . {by using magnetic beads}
- 15/1017 . . . . . {by filtration, e.g. using filters, frits, membranes}
- 15/102 . . . . {Mutagenizing nucleic acids}
- 15/1024 . . . . . {In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair}
- 15/1027 . . . . . {by DNA shuffling, e.g. RSR, STEP, RPR}
- 15/1031 . . . . . {mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR}
- 15/1034 . . . . {Isolating an individual clone by screening libraries}
- 15/1037 . . . . . {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- 15/1041 . . . . . {Ribosome/Polysome display, e.g. SPERT, ARM}
- 15/1044 . . . . . {Preparation or screening of libraries displayed on scaffold proteins}
- 15/1048 . . . . . {SELEX}
- 15/1051 . . . . . {Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors}
- 15/1055 . . . . . {Protein x Protein interaction, e.g. two hybrid selection}
- 15/1058 . . . . . {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- 15/1062 . . . . . {mRNA-Display, e.g. polypeptide and encoding template are connected covalently}
- 15/1065 . . . . . {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- 15/1068 . . . . . {Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}
- 15/1072 . . . . . {Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
- 15/1075 . . . . . {by coupling phenotype to genotype, not provided for in other groups of this subclass}
- 15/1079 . . . . . {Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays [C12N 15/1086](#))}
- 15/1082 . . . . . {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- 15/1086 . . . . . {Preparation or screening of expression libraries, e.g. reporter assays}
- 15/1089 . . . . . {Design, preparation, screening or analysis of libraries using computer algorithms}
- 15/1093 . . . . . {General methods of preparing gene libraries, not provided for in other subgroups}
- 15/1096 . . . . {cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}



- 15/11 . . DNA or RNA fragments; Modified forms thereof ([DNA or RNA not used in recombinant technology, C07H 21/00](#)); {Non-coding nucleic acids having a biological activity}
- NOTE**
- Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups [C12N 15/11](#) - [C12N 15/117](#) cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The [C12N 2303/00](#) ICO scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group [C12N 15/111](#)
- 15/111 . . . {General methods applicable to biologically active non-coding nucleic acids}
- 15/113 . . . Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing ([when used in plants C12N 15/8218](#))}
- 15/1131 . . . . {against viruses}
- 15/1132 . . . . . {against retroviridae, e.g. HIV}
- 15/1133 . . . . . {against herpetoviridae, e.g. HSV}
- 15/1135 . . . . . {against oncogenes or tumor suppressor genes}
- 15/1136 . . . . . {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- 15/1137 . . . . . {against enzymes ([viral enzymes C12N 15/1131](#); [receptors C12N 15/1138](#))}
- 15/1138 . . . . . {against receptors or cell surface proteins}
- 15/115 . . . Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- NOTE**
- Aptamers fused to compounds which are already classified in groups [C12N 15/11](#) - [C12N 15/117](#), are classified with the corresponding compound
- 15/117 . . . Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- 15/52 . . . Genes encoding for enzymes or proenzymes
- NOTE**
- In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.
- 15/62 . . . DNA sequences coding for fusion proteins
- NOTE**
- In this group, the following term is used with the meaning indicated:
- "fusion" means the fusion of two different proteins.
- 15/625 . . . . . {containing a sequence coding for a signal sequence}
- 15/63 . . Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- 15/635 . . . {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracycline}
- 15/64 . . . General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
- NOTE**
- {In the group [C12N 15/64](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}
- 15/65 . . . using markers ([enzymes used as markers C12N 15/52](#))
- NOTE**
- {In the group [C12N 15/65](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}
- 15/66 . . . General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
- NOTES**
- In this group, the following expression is used with the meaning indicated:
    - "non-functional linkers" means DNA sequences which are used to link DNA sequences and which have no known function of structural gene or regulating function.
  - {In the group [C12N 15/66](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}
- 15/67 . . . General methods for enhancing the expression
- 15/68 . . . . Stabilisation of the vector
- 15/69 . . . . Increasing the copy number of the vector
- 15/70 . . . Vectors or expression systems specially adapted for E. coli
- NOTES**
- This group [covers](#) the use of E. coli as host.
  - Shuttle vectors also replicating in E. coli are classified according to the other host.

15/71	. . . . Expression systems using regulatory sequences derived from the trp-operon		are not systematically classified in <a href="#">C12N 15/8209</a>
15/72	. . . . Expression systems using regulatory sequences derived from the lac-operon	15/821	. . . . . {Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers}
15/73	. . . . Expression systems using phage (lambda) regulatory sequences	15/8212	. . . . . {Colour markers, e.g. beta-glucuronidase [GUS], green fluorescent protein [GFP], carotenoid}
15/74	. . . Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora	15/8213	. . . . . {Targeted insertion of genes into the plant genome by homologous recombination}
	<b>NOTE</b> This group <u>covers</u> the use of prokaryotes as hosts.	15/8214	. . . . . {Plastid transformation}
15/743	. . . . {for Agrobacterium; Rhizobium; Bradyrhizobium}	15/8216	. . . . . {Methods for controlling, regulating or enhancing expression of transgenes in plant cells}
15/746	. . . . {for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)}	15/8217	. . . . . {Gene switch}
15/75	. . . . for Bacillus	15/8218	. . . . . {Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}
15/76	. . . . for Actinomyces; for Streptomyces	15/822	. . . . . {Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression}
15/77	. . . . for Corynebacterium; for Brevibacterium	15/8221	. . . . . {Transit peptides}
15/78	. . . . for Pseudomonas	15/8222	. . . . . {Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation}
15/79	. . . Vectors or expression systems specially adapted for eukaryotic hosts	15/8223	. . . . . {Vegetative tissue-specific promoters}
	<b>NOTE</b> This group <u>covers</u> the use of eukaryotes as hosts.	15/8225	. . . . . {Leaf-specific, e.g. including petioles, stomata}
15/80	. . . . for fungi	15/8226	. . . . . {Stem-specific, e.g. including tubers, beets}
15/81	. . . . . for yeasts	15/8227	. . . . . {Root-specific}
15/815	. . . . . {for yeasts other than Saccharomyces}	15/8229	. . . . . {Meristem-specific, e.g. nodal, apical}
15/82	. . . . for plant cells {, e.g. plant artificial chromosomes (PACs)}	15/823	. . . . . {Reproductive tissue-specific promoters}
	<b>WARNING</b> Documents are being continuously reclassified into this new classification scheme. See Warning notes below	15/8231	. . . . . {Male-specific, e.g. anther, tapetum, pollen}
15/8201	. . . . . {Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation}	15/8233	. . . . . {Female-specific, e.g. pistil, ovule}
15/8202	. . . . . {by biological means, e.g. cell mediated or natural vector}	15/8234	. . . . . {Seed-specific, e.g. embryo, endosperm}
15/8203	. . . . . {Virus mediated transformation}	15/8235	. . . . . {Fruit-specific}
15/8205	. . . . . {Agrobacterium mediated transformation}	15/8237	. . . . . {Externally regulated expression systems}
15/8206	. . . . . {by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated}	15/8238	. . . . . {chemically inducible, e.g. tetracycline}
15/8207	. . . . . {by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers}	15/8239	. . . . . {pathogen inducible}
15/8209	. . . . . {Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers}	15/8241	. . . . . {Phenotypically and genetically modified plants via recombinant DNA technology}
	<b>NOTE</b> Standard selectable markers such as neomycin phosphotransferase (NPT)	15/8242	. . . . . {with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits}
		15/8243	. . . . . {involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine}
		15/8245	. . . . . {involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis}

15/8246	. . . . .	{Non-starch polysaccharides, e.g. cellulose, fructans, levans}	15/8295	. . . . .	{Cytokinins}
15/8247	. . . . .	{involving modified lipid metabolism, e.g. seed oil composition}	15/8297	. . . . .	{Gibberellins; GA3}
15/8249	. . . . .	{involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life}	15/8298	. . . . .	{Brassinosteroids}
15/825	. . . . .	{involving pigment biosynthesis}	15/85	. . . . .	for animal cells
		<b>NOTE</b>	15/8509	. . . . .	{for producing genetically modified animals, e.g. transgenic}
		Transgenic plants with altered flower morphology are also classified in this group			<b>NOTE</b>
15/8251	. . . . .	{Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis}	2015/8518	. . . . .	{expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
15/8253	. . . . .	{Methionine or cysteine}	2015/8527	. . . . .	{for producing animal models, e.g. for tests or diseases}
15/8254	. . . . .	{Tryptophan or lysine}	2015/8536	. . . . .	{Animal models for genetic diseases}
15/8255	. . . . .	{involving lignin biosynthesis}	2015/8545	. . . . .	{for Alzheimer's disease}
15/8257	. . . . .	{for the production of primary gene products, e.g. pharmaceutical products, interferon}	2015/8554	. . . . .	{Invertebrates models for Alzheimer's disease}
15/8258	. . . . .	{for the production of oral vaccines (antigens) or immunoglobulins}	2015/8563	. . . . .	{for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus}
15/8259	. . . . .	{Phytoremediation}	2015/8572	. . . . .	{Animal models for proliferative diseases, e.g. comprising an oncogene}
15/8261	. . . . .	{with agronomic (input) traits, e.g. crop yield}	2015/8581	. . . . .	{Animal models for infectious diseases, e.g. AIDS}
15/8262	. . . . .	{involving plant development}	2015/859	. . . . .	{Animal models comprising reporter system for screening tests}
15/8263	. . . . .	{Ablation; Apoptosis}	15/86	. . . . .	Viral vectors
15/8265	. . . . .	{Transgene containment, e.g. gene dispersal}			<b>WARNING</b>
15/8266	. . . . .	{Abscission; Dehiscence; Senescence}			From March 15, 2012 groups <a href="#">C12N 15/861</a> - <a href="#">C12N 15/869</a> and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range <a href="#">C12N 2710/00-C12N 2795/00</a>
15/8267	. . . . .	{Seed dormancy, germination or sprouting}			
15/8269	. . . . .	{Photosynthesis}			
15/827	. . . . .	{Flower development or morphology, e.g. flowering promoting factor [FPF]}	15/861	. . . . .	Adenoviral vectors
15/8271	. . . . .	{for stress resistance, e.g. heavy metal resistance}	15/8613	. . . . .	{Chimaeric vector systems comprising heterologous sequences for production of another viral vector}
15/8273	. . . . .	{for drought, cold, salt resistance}	15/8616	. . . . .	{Special methods for targeting systems}
15/8274	. . . . .	{for herbicide resistance}	15/863	. . . . .	Poxviral vectors, {e.g. entomopoxvirus}
15/8275	. . . . .	{Glyphosate}	15/8633	. . . . .	{Avian poxviral vectors}
15/8277	. . . . .	{Phosphinotricin}	15/8636	. . . . .	{Vaccina virus vectors}
15/8278	. . . . .	{Sulfonylurea}	15/864	. . . . .	Parvoviral vectors {, e.g. parvovirus, densovirus}
15/8279	. . . . .	{for biotic stress resistance, pathogen resistance, disease resistance}	15/8645	. . . . .	{Adeno-associated virus}
15/8281	. . . . .	{for bacterial resistance}	15/866	. . . . .	Baculoviral vectors
15/8282	. . . . .	{for fungal resistance}	15/867	. . . . .	Retroviral vectors
15/8283	. . . . .	{for virus resistance}	15/8673	. . . . .	{Special methods for packaging systems}
15/8285	. . . . .	{for nematode resistance}	15/8676	. . . . .	{Special methods for targeting systems}
15/8286	. . . . .	{for insect resistance}	15/869	. . . . .	Herpesviral vectors
15/8287	. . . . .	{for fertility modification, e.g. apomixis}	15/8695	. . . . .	{Herpes simplex virus-based vectors}
15/8289	. . . . .	{Male sterility}			
15/829	. . . . .	{Female sterility}			
15/8291	. . . . .	{Hormone-influenced development}			
15/8293	. . . . .	{Abscisic acid [ABA]}			
15/8294	. . . . .	{Auxins}			

- 15/87 . . Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- 15/873 . . . Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- 15/877 . . . . Techniques for producing new mammalian cloned embryos
- 15/8771 . . . . . {Bovine embryos}
- 15/8772 . . . . . {Caprine embryos}
- 15/8773 . . . . . {Ovine embryos}
- 15/8775 . . . . . {Murine embryos}
- 15/8776 . . . . . {Primate embryos}
- 15/8777 . . . . . {Rabbit embryos}
- 15/8778 . . . . . {Swine embryos}
- 15/88 . . . using microencapsulation, e.g. using {amphiphile} liposome vesicle
- 15/89 . . . using microinjection
- 15/895 . . . . {using biolistic methods}
- 15/90 . . . Stable introduction of foreign DNA into chromosome
- 15/902 . . . . {using homologous recombination}
- 15/905 . . . . . {in yeast}
- 15/907 . . . . . {in mammalian cells}
- 2303/00** **Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids**
- NOTE**
- Indexing codes of group [C12N 2303/00](#) are only used in combination with group [C12N 15/111](#)
- 2310/00** **Structure or type of the nucleic acid**
- NOTE**
- In groups [C12N 2310/00](#) - [C12N 2310/533](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#).
- 2310/10 . Type of nucleic acid
- 2310/11 . . Antisense
- 2310/111 . . . spanning the whole gene, or a large part of it
- 2310/113 . . . targeting other non-coding nucleic acids, e.g. antagomirs
- 2310/12 . . catalytic nucleic acids, e.g. ribozymes
- 2310/121 . . . Hammerhead
- 2310/122 . . . Hairpin
- 2310/123 . . . Hepatitis delta
- 2310/124 . . . based on group I or II introns
- 2310/1241 . . . . Tetrahymena
- 2310/126 . . . involving RNase P
- 2310/127 . . . DNAzymes
- 2310/128 . . . processing or releasing ribozyme
- 2310/13 . . Decoys
- 2310/14 . . interfering N.A.
- 2310/141 . . . MicroRNAs, miRNAs
- 2310/15 . . Nucleic acids forming more than 2 strands, e.g. TFOs
- 2310/151 . . . more than 3 strands, e.g. tetrads, H-DNA
- 2310/152 . . . on a single-stranded target, e.g. fold-back TFOs
- 2310/153 . . . with the aid of a protein, e.g. recombinase
- 2310/16 . . Aptamers
- 2310/17 . . Immunomodulatory nucleic acids
- 2310/18 . . acting by a non-sequence specific mechanism (other than [C12N 2310/16](#) or [C12N 2310/17](#))
- 2310/20 . . involving clustered regularly interspaced short palindromic repeats [CRISPRs]
- 2310/30 . Chemical structure
- 2310/31 . . of the backbone
- 2310/311 . . . Phosphotriesters
- 2310/312 . . . Phosphonates
- 2310/3125 . . . . Methylphosphonates
- 2310/313 . . . Phosphorodithioates
- 2310/314 . . . Phosphoramidates
- 2310/3145 . . . . with the nitrogen in 3' or 5'-position
- 2310/315 . . . Phosphorothioates
- 2310/316 . . . Phosphonothioates
- 2310/317 . . . with an inverted bond, e.g. a cap structure
- 2310/318 . . . where the PO2 is completely replaced, e.g. MMI or formacetal
- 2310/3181 . . . . Peptide nucleic acid, PNA
- 2310/3183 . . . . Diol linkers, e.g. glycols or propanediols
- 2310/319 . . . linked by 2'-5' linkages, i.e. having a free 3'-position
- 2310/32 . . of the sugar
- 2310/321 . . . 2'-O-R Modification
- 2310/322 . . . 2'-R Modification
- 2310/323 . . . modified ring structure
- 2310/3231 . . . . having an additional ring, e.g. LNA, ENA
- 2310/3233 . . . . Morpholino-type ring
- 2310/3235 . . . . having the O of the ribose replaced by another atom
- 2310/33 . . of the base
- 2310/331 . . . Universal or degenerate base
- 2310/332 . . . Abasic residue
- 2310/333 . . . Modified A
- 2310/334 . . . Modified C
- 2310/3341 . . . . 5-Methylcytosine
- 2310/335 . . . Modified T or U
- 2310/336 . . . Modified G
- 2310/337 . . . in alpha-anomeric form
- 2310/34 . . Spatial arrangement of the modifications
- 2310/341 . . . Gappers, i.e. of the type =====
- 2310/342 . . . Hemimers, i.e. of the type =====
- 2310/343 . . . having patterns, e.g. --------
- 2310/344 . . . Position-specific modifications, e.g. on every purine, at the 3'-end
- 2310/345 . . . having at least two different backbone modifications
- 2310/346 . . . having a combination of backbone and sugar modifications
- 2310/35 . . Nature of the modification
- 2310/351 . . . Conjugate
- 2310/3511 . . . . intercalating or cleaving agent
- 2310/3513 . . . . Protein; Peptide
- 2310/3515 . . . . Lipophilic moiety, e.g. cholesterol
- 2310/3517 . . . . Marker; Tag
- 2310/3519 . . . . Fusion with another nucleic acid
- 2310/352 . . . linked to the nucleic acid via a carbon atom
- 2310/3521 . . . . Methyl
- 2310/3523 . . . . Allyl
- 2310/3525 . . . . MOE, methoxyethoxy
- 2310/3527 . . . . Other alkyl chain

- 2310/3529 . . . . Aromatic substituent
- 2310/353 . . . linked to the nucleic acid via an atom other than carbon
- 2310/3531 . . . . Hydrogen
- 2310/3533 . . . . Halogen
- 2310/3535 . . . . Nitrogen
- 2310/50 . Physical structure
- 2310/51 . . in polymeric form, e.g. multimers, concatemers
- 2310/52 . . branched
- 2310/53 . . partially self-complementary or closed
- 2310/531 . . . Stem-loop; Hairpin
- 2310/532 . . . Closed or circular
- 2310/533 . . . having a mismatch or nick in at least one of the strands
- 2320/00 Applications; Uses**
- 2320/10 . in screening processes
- 2320/11 . . for the determination of target sites, i.e. of active nucleic acids
- 2320/12 . . in functional genomics, i.e. for the determination of gene function
- 2320/13 . . in a process of directed evolution, e.g. SELEX, acquiring a new function
- 2320/30 . Special therapeutic applications
- 2320/31 . . Combination therapy
- 2320/32 . . Special delivery means, e.g. tissue-specific
- 2320/33 . . Alteration of splicing
- 2320/34 . . Allele or polymorphism specific uses
- 2320/35 . . based on a specific dosage / administration regimen
- 2320/50 . Methods for regulating/modulating their activity
- 2320/51 . . modulating the chemical stability, e.g. nuclease-resistance
- 2320/52 . . modulating the physical stability, e.g. GC-content
- 2320/53 . . reducing unwanted side-effects
- 2330/00 Production**
- 2330/10 . naturally occurring
- 2330/30 . chemically synthesised
- 2330/31 . . Libraries, arrays
- 2330/50 . Biochemical production, i.e. in a transformed host cell
- 2330/51 . . Specially adapted vectors
- 2500/00 Specific components of cell culture medium**
- 2500/02 . Atmosphere, e.g. low oxygen conditions
- 2500/05 . Inorganic components
- 2500/10 . . Metals; Metal chelators ([cobalamine C12N 2500/38](#))
- 2500/12 . . . Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- 2500/14 . . . . Calcium; Ca chelators; Calcitonin
- 2500/16 . . . . Magnesium; Mg chelators
- 2500/20 . . . Transition metals
- 2500/22 . . . . Zinc; Zn chelators ([insulin-zinc complexes C12N 2501/33](#))
- 2500/24 . . . . Iron; Fe chelators; Transferrin
- 2500/25 . . . . Insulin-transferrin; Insulin-transferrin-selenium
- 2500/30 . Organic components ([metal chelators C12N 2500/10](#); [calcitonin C12N 2500/14](#); [transferrin C12N 2500/24](#))
- 2500/32 . . Amino acids
- 2500/33 . . . other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
- 2500/34 . . Sugars
- 2500/35 . . Polyols, e.g. glycerin, inositol
- 2500/36 . . Lipids
- 2500/38 . . Vitamins
- 2500/40 . . Nucleotides, nucleosides, bases ([cyclic nucleotides C12N 2501/01](#), [anti-neoplastic drugs C12N 2501/06](#))
- 2500/42 . . Organic phosphate, e.g. beta glycerophosphate
- 2500/44 . . Thiols, e.g. mercaptoethanol
- 2500/46 . . Amines, e.g. putrescine
- 2500/50 . Soluble polymers, e.g. polyethyleneglycol [PEG]
- 2500/60 . Buffer, e.g. pH regulation, osmotic pressure
- 2500/62 . . DMSO
- 2500/70 . Undefined extracts ([conditioned medium C12N 2502/00](#))
- 2500/72 . . from bacteria
- 2500/74 . . from fungi, e.g. yeasts
- 2500/76 . . from plants
- 2500/78 . . from protozoa
- 2500/80 . . from animals
- 2500/82 . . . from invertebrates
- 2500/84 . . . from mammals
- 2500/90 . Serum-free medium, which may still contain naturally-sourced components
- 2500/92 . . Medium free of human- or animal-derived components
- 2500/95 . . Protein-free medium and culture conditions
- 2500/98 . Xeno-free medium and culture conditions
- 2500/99 . Serum-free medium
- WARNING**
- This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to [C12N 2500/90](#) - [C12N 2500/98](#)
- 2501/00 Active agents used in cell culture processes, e.g. differentiation**
- NOTE**
- Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in [C07K 14/00](#), but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.
- 2501/01 . Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- 2501/02 . Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
- 2501/03 . Compounds acting on the NO pathway, e.g. nitrososarginine
- 2501/04 . Immunosuppressors, e.g. cyclosporin, tacrolimus
- 2501/05 . Adjuvants
- 2501/051 . . Lipid A (MPA, MPL)
- 2501/052 . . Lipopolysaccharides [LPS]

- 2501/054 . . Muramyle peptides
- 2501/056 . . Immunostimulating oligonucleotides, e.g. CpG
- 2501/06 . . Anti-neoplastic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
- 2501/065 . . Modulators of histone acetylation
- 2501/07 . . Heat shock proteins
- 2501/10 . . Growth factors
- 2501/105 . . Insulin-like growth factors [IGF]
- 2501/11 . . Epidermal growth factor [EGF]
- 2501/113 . . Acidic fibroblast growth factor (aFGF, FGF-1)
- 2501/115 . . Basic fibroblast growth factor (bFGF, FGF-2)
- 2501/117 . . Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
- 2501/119 . . Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- 2501/12 . . Hepatocyte growth factor [HGF]
- 2501/125 . . Stem cell factor [SCF], c-kit ligand [KL]
- 2501/13 . . Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- 2501/135 . . Platelet-derived growth factor [PDGF]
- 2501/14 . . Erythropoietin [EPO]
- 2501/145 . . Thrombopoietin [TPO]
- 2501/148 . . Transforming growth factor alpha [TGF- $\alpha$ ]
- 2501/15 . . Transforming growth factor beta (TGF- $\beta$ )
- 2501/155 . . Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- 2501/16 . . Activin; Inhibin; Mullerian inhibiting substance
- 2501/165 . . Vascular endothelial growth factor [VEGF]
- 2501/17 . . Angiopoietin
- 2501/175 . . Cardiotrophin
- 2501/18 . . Liver cell growth factor (LCGF, Gly-His-Lys)
- 2501/185 . . Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL)
- 2501/19 . . Growth and differentiation factors [GDF]
- 2501/195 . . Heregulin, neu differentiation factor
- 2501/20 . . Cytokines; Chemokines
- 2501/21 . . Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
- 2501/22 . . Colony stimulating factors (G-CSF, GM-CSF)
- 2501/23 . . Interleukins [IL]
- 2501/2301 . . . Interleukin-1 (IL-1)
- 2501/2302 . . . Interleukin-2 (IL-2)
- 2501/2303 . . . Interleukin-3 (IL-3)
- 2501/2304 . . . Interleukin-4 (IL-4)
- 2501/2305 . . . Interleukin-5 (IL-5)
- 2501/2306 . . . Interleukin-6 (IL-6)
- 2501/2307 . . . Interleukin-7 (IL-7)
- 2501/2308 . . . Interleukin-8 (IL-8)
- 2501/2309 . . . Interleukin-9 (IL-9)
- 2501/231 . . . Interleukin-10 (IL-10)
- 2501/2311 . . . Interleukin-11 (IL-11)
- 2501/2312 . . . Interleukin-12 (IL-12)
- 2501/2313 . . . Interleukin-13 (IL-13)
- 2501/2314 . . . Interleukin-14 (IL-14)
- 2501/2315 . . . Interleukin-15 (IL-15)
- 2501/2316 . . . Interleukin-16 (IL-16)
- 2501/2317 . . . Interleukin-17 (IL-17)
- 2501/2318 . . . Interleukin-18 (IL-18)
- 2501/2319 . . . Interleukin-19 (IL-19)
- 2501/232 . . . Interleukin-20 (IL-20)
- 2501/2321 . . . Interleukin-21 (IL-21)
- 2501/2322 . . . Interleukin-22 (IL-22)
- 2501/2323 . . . Interleukin-23 (IL-23)
- 2501/2324 . . . Interleukin-24 (IL-24)
- 2501/2325 . . . Interleukin-25 (IL-25)
- 2501/2326 . . . Interleukin-26 (IL-26)
- 2501/2327 . . . Interleukin-27 (IL-27)
- 2501/2328 . . . Interleukin-28 (IL-28)
- 2501/2329 . . . Interleukin-29 (IL-29)
- 2501/233 . . . Interleukin-30 (IL-30)
- 2501/2331 . . . Interleukin-31 (IL-31)
- 2501/2332 . . . Interleukin-32 (IL-32)
- 2501/2333 . . . Interleukin-33 (IL-33)
- 2501/2334 . . . Interleukin-34 (IL-34)
- 2501/2335 . . . Interleukin-35 (IL-35)
- 2501/235 . . . Leukemia inhibitory factor [LIF]
- 2501/237 . . Oncostatin M [OSM]
- 2501/24 . . Interferons [IFN]
- 2501/25 . . Tumour necrosing factors [TNF]
- 2501/26 . . Flt-3 ligand (CD135L, flk-2 ligand)
- 2501/30 . . Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin [C12N 2501/85](#))
- 2501/305 . . Growth hormone [GH], aka. somatotropin
- 2501/31 . . Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
- 2501/315 . . Prolactin
- 2501/32 . . Angiotensins [AT], angiotensinogen
- 2501/33 . . Insulin (together with transferrin [C12N 2500/25](#); Insulin-like growth factors [C12N 2501/105](#))
- 2501/335 . . Glucagon; Glucagon-like peptide [GLP]; Exendin
- 2501/34 . . Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin
- 2501/345 . . Gastrin; Cholecystokinins [CCK]
- 2501/35 . . Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]
- 2501/355 . . Leptin
- 2501/36 . . Somatostatin
- 2501/365 . . Endothelin
- 2501/37 . . Parathyroid hormone [PTH]
- 2501/375 . . Thyroid stimulating hormone [TSH]
- 2501/38 . . with nuclear receptors
- 2501/385 . . . of the family of the retinoic acid receptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- 2501/39 . . . Steroid hormones
- 2501/392 . . . . Sexual steroids
- 2501/395 . . . Thyroid hormones
- 2501/40 . . Regulators of development
- 2501/405 . . Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
- 2501/41 . . Hedgehog proteins; Cyclopamine (inhibitor)
- 2501/415 . . Wnt; Frizzled
- 2501/42 . . Notch; Delta; Jagged; Serrate
- 2501/48 . . Regulators of apoptosis
- 2501/50 . . Cell markers; Cell surface determinants
- 2501/505 . . CD4; CD8
- 2501/51 . . B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- 2501/515 . . CD3, T-cell receptor complex

C12N

2501/52	. . CD40, CD40-ligand (CD154)	2502/083	. . sensory transducers
2501/53	. . CD2	2502/085	. . eye cells
2501/58	. . Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)	2502/086	. . glial cells
2501/585	. . Integrins	2502/088	. . neural stem cells
2501/59	. . Lectins	2502/09	. . epidermal cells, skin cells, oral mucosa cells
2501/599	. . with CD designations not provided for elsewhere	2502/091	. . melanocytes
2501/60	. . Transcription factors	2502/092	. . hair cells
2501/602	. . Sox-2	2502/094	. . keratinocytes
2501/603	. . Oct-3/4	2502/095	. . mammary cells
2501/604	. . Klf-4	2502/097	. . oral mucosa cells
2501/605	. . Nanog	2502/098	. . cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands
2501/606	. . c-Myc	2502/11	. . blood or immune system cells
2501/608	. . Lin28	2502/1107	. . B cells
2501/65	. . MicroRNA	2502/1114	. . T cells
2501/70	. . Enzymes	2502/1121	. . Dendritic cells
2501/71	. . Oxidoreductases (EC 1.)	2502/1128	. . Erythrocytes
2501/72	. . Transferases (EC 2.) ( <a href="#">acetylation of histones C12N 2501/065</a> )	2502/1135	. . Granulocytes
2501/724	. . . Glycosyltransferases (EC 2.4.)	2502/1142	. . Osteoclasts
2501/727	. . . Kinases (EC 2.7.)	2502/115	. . Platelets, megakaryocytes
2501/73	. . Hydrolases (EC 3.)	2502/1157	. . Monocytes, macrophages
2501/734	. . . Proteases (EC 3.4.)	2502/1164	. . NK cells
2501/80	. . Neurotransmitters; Neurohormones	2502/1171	. . Haematopoietic stem cells
2501/805	. . Acetylcholine	2502/1178	. . Spleen cells
2501/81	. . Adrenaline	2502/1185	. . Thymus cells
2501/815	. . Dopamine	2502/1192	. . Lymphatic cells
2501/82	. . Histamine	2502/13	. . connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
2501/825	. . Serotonine (5-HT); Melatonin	2502/1305	. . Adipocytes
2501/83	. . Tachykinins, e.g. substance P	2502/1311	. . Osteocytes, osteoblasts, odontoblasts
2501/835	. . Neuropeptide Y [NPY]; Peptide YY [PYY]	2502/1317	. . Chondrocytes
2501/84	. . Excitatory amino acids	2502/1323	. . Adult fibroblasts
2501/845	. . Gamma amino butyric acid [GABA]	2502/1329	. . Cardiomyocytes
2501/85	. . Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin	2502/1335	. . Skeletal muscle cells, myocytes, myoblasts, myotubes
2501/855	. . Corticotropin [ACTH]	2502/1341	. . Tenocytes, cells from tendons and ligaments
2501/86	. . Melanocyte-stimulating hormone [MSH]	2502/1347	. . Smooth muscle cells
2501/90	. . Polysaccharides	2502/1352	. . Mesenchymal stem cells
2501/905	. . Hyaluronic acid	2502/1358	. . . Bone marrow mesenchymal stem cells (BM- MSC)
2501/91	. . Heparin	2502/1364	. . . Dental pulp stem cells, dental follicle stem cells
2501/998	. . Proteins not provided for elsewhere	2502/137	. . . Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood
	<b>NOTE</b>	2502/1376	. . . Mesenchymal stem cells from hair follicles
	Classification by pathway does not apply.	2502/1382	. . . Adipose-derived stem cells [ADSC], adipose stromal stem cells
2501/999	. . Small molecules not provided for elsewhere	2502/1388	. . . Mesenchymal stem cells from other natural sources
	<b>NOTE</b>	2502/1394	. . Bone marrow stromal cells; whole marrow
	Classification by pathway does not apply.	2502/14	. . hepatocytes
<b>2502/00</b>	<b>Coculture with; Conditioned medium produced by</b>	2502/22	. . pancreatic cells
2502/02	. . embryonic cells	2502/23	. . Gastro-intestinal tract cells
2502/025	. . extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly	2502/24	. . Genital tract cells, non-germinal cells from gonads
2502/03	. . non-embryonic pluripotent stem cells	2502/243	. . Cells of the female genital tract, non-germinal ovarian cells
2502/04	. . germ cells	2502/246	. . Cells of the male genital tract, non-germinal testis cells
2502/07	. . endocrine cells	2502/25	. . Urinary tract cells, renal cells
2502/072	. . adrenal cells	2502/253	. . Bladder cells
2502/074	. . pinealocytes	2502/256	. . Renal cells
2502/076	. . pituitary cells	2502/27	. . Lung cells, respiratory tract cells
2502/078	. . thyroid, parathyroid cells	2502/28	. . Vascular endothelial cells
2502/08	. . cells of the nervous system		
2502/081	. . neurons		

## C12N

- 2502/30 . . . tumour cells
- 2502/45 . . . Artificially induced pluripotent stem cells
- 2502/50 . . . invertebrate cells
- 2502/70 . . . Non-animal cells
- 2502/99 . . . genetically modified cells

### NOTE

Use [C12N 2501/00](#) to index the expressed products.

### 2503/00 Use of cells in diagnostics

- 2503/02 . . . Drug screening
- 2503/04 . . . Screening or testing on artificial tissues
- 2503/06 . . . Screening or testing on artificial skin

### 2506/00 Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells

#### NOTE

This scheme indexes the starting point of a differentiation process and is used in combination with classification in [C12N 5/06](#) for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

- 2506/02 . . . from embryonic cells
- 2506/025 . . . from extra-embryonic cells, e.g. trophoblast, placenta
- 2506/03 . . . from non-embryonic pluripotent stem cells
- 2506/04 . . . from germ cells
- 2506/07 . . . from endocrine cells
- 2506/072 . . . from adrenal cells
- 2506/074 . . . from pinealocytes
- 2506/076 . . . from pituitary cells
- 2506/078 . . . from thyroid, parathyroid cells
- 2506/08 . . . from cells of the nervous system
- 2506/09 . . . from epidermal cells, from skin cells, from oral mucosa cells
- 2506/091 . . . from melanocytes
- 2506/092 . . . from hair cells
- 2506/094 . . . from keratinocytes
- 2506/095 . . . from mammary cells
- 2506/097 . . . from oral mucosa cells
- 2506/098 . . . from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
- 2506/11 . . . from blood or immune system cells
- 2506/115 . . . from monocytes, from macrophages
- 2506/13 . . . from connective tissue cells, from mesenchymal cells
- 2506/1307 . . . from adult fibroblasts
- 2506/1315 . . . from cardiomyocytes
- 2506/1323 . . . from skeletal muscle cells
- 2506/133 . . . from tenocytes
- 2506/1338 . . . from smooth muscle cells
- 2506/1346 . . . from mesenchymal stem cells
- 2506/1353 . . . from bone marrow mesenchymal stem cells (BM-MSc)
- 2506/1361 . . . from dental pulp or dental follicle stem cells
- 2506/1369 . . . from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
- 2506/1376 . . . from mesenchymal stem cells derived from hair follicles

- 2506/1384 . . . from adipose-derived stem cells [ADSC], from adipose stromal stem cells
- 2506/1392 . . . from mesenchymal stem cells from other natural sources
- 2506/14 . . . from hepatocytes
- 2506/22 . . . from pancreatic cells
- 2506/23 . . . from cells of the gastro-intestinal tract
- 2506/24 . . . from cells of the genital tract, from non-germinal gonad cells
- 2506/243 . . . from cells of the female genital tract cells, from non-germinal ovarian cells
- 2506/246 . . . from cells of the male genital tract cells, from non-germinal testis cells
- 2506/25 . . . from renal cells, from cells of the urinary tract
- 2506/27 . . . from lung cells, from cells of the respiratory tract
- 2506/28 . . . from vascular endothelial cells
- 2506/30 . . . from cancer cells, e.g. reversion of tumour cells

### NOTE

Unless the tumourigenic phenotype is totally reversed, the end product is still classified under [C12N 5/0693](#).

- 2506/45 . . . from artificially induced pluripotent stem cells
- 2509/00 **Methods for the dissociation of cells, e.g. specific use of enzymes**
- 2509/10 . . . Mechanical dissociation
- 2510/00 **Genetically modified cells**
- 2510/02 . . . Cells for production
- 2510/04 . . . Immortalised cells
- 2511/00 **Cells for large scale production**
- 2513/00 **3D culture**
- 2517/00 **Cells related to new breeds of animals**
- 2517/02 . . . Cells from transgenic animals
- 2517/04 . . . Cells produced using nuclear transfer
- 2517/10 . . . Conditioning of cells for *in vitro* fecondation or nuclear transfer
- 2521/00 **Culture process characterised by the use of hydrostatic pressure, flow or shear forces**
- 2521/10 . . . Sound, e.g. ultrasounds
- 2523/00 **Culture process characterised by temperature**
- 2525/00 **Culture process characterised by gravity, e.g. microgravity**
- 2527/00 **Culture process characterised by the use of mechanical forces, e.g. strain, vibration**
- 2529/00 **Culture process characterised by the use of electromagnetic stimulation**
- 2529/10 . . . Stimulation by light
- 2531/00 **Microcarriers**
- 2533/00 **Supports or coatings for cell culture, characterised by material**
- 2533/10 . . . Mineral substrates
- 2533/12 . . . Glass
- 2533/14 . . . Ceramic
- 2533/18 . . . Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
- 2533/20 . . . Small organic molecules



- 2533/30 . Synthetic polymers ([thermoreactive polymers](#), e.g. [PNIPAm](#), [C12N 2539/10](#))
- 2533/32 . . Polylysine, polyornithine
- 2533/40 . . Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
- 2533/50 . Proteins
- 2533/52 . . Fibronectin; Laminin
- 2533/54 . . Collagen; Gelatin
- 2533/56 . . Fibrin; Thrombin
- 2533/70 . Polysaccharides
- 2533/72 . . Chitin, chitosan
- 2533/74 . . Alginate
- 2533/76 . . Agarose, agar-agar
- 2533/78 . . Cellulose
- 2533/80 . . Hyaluronan
- 2533/90 . Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- 2533/92 . . Amnion; Decellularised dermis or mucosa
- 2535/00 Supports or coatings for cell culture characterised by topography**
- 2535/10 . Patterned coating
- 2537/00 Supports and/or coatings for cell culture characterised by physical or chemical treatment**
- 2537/10 . Cross-linking
- 2539/00 Supports and/or coatings for cell culture characterised by properties**
- 2539/10 . Coating allowing for selective detachment of cells, e.g. thermoreactive coating
- Viruses**
- 2710/00 dsDNA viruses**
- 2710/00011 . Details
- 2710/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/00023 . . Virus like particles [VLP]
- 2710/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/00041 . . Use of virus, viral particle or viral elements as a vector
- 2710/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/00043 . . . viral genome or elements thereof as genetic vector
- 2710/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/00045 . . . Special targeting system for viral vectors
- 2710/00051 . . Methods of production or purification of viral material
- 2710/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/00061 . . Methods of inactivation or attenuation
- 2710/00062 . . . by genetic engineering
- 2710/00063 . . . by chemical treatment
- 2710/00064 . . . by serial passage
- 2710/00071 . . Demonstrated in vivo effect
- 2710/00088 . . for redistribution
- 2710/10011 . . Adenoviridae
- 2710/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10023 . . . Virus like particles [VLP]
- 2710/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10043 . . . . viral genome or elements thereof as genetic vector
- 2710/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10045 . . . . Special targeting system for viral vectors
- 2710/10051 . . . Methods of production or purification of viral material
- 2710/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10061 . . . Methods of inactivation or attenuation
- 2710/10062 . . . . by genetic engineering
- 2710/10063 . . . . by chemical treatment
- 2710/10064 . . . . by serial passage
- 2710/10071 . . . Demonstrated in vivo effect
- 2710/10088 . . . for redistribution
- 2710/10111 . . . Atadenovirus, e.g. ovine adenovirus D
- 2710/10121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10123 . . . . Virus like particles [VLP]
- 2710/10131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

- 2710/10141 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/10142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10143 . . . . . viral genome or elements thereof as genetic vector
- 2710/10144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10145 . . . . . Special targeting system for viral vectors
- 2710/10151 . . . . . Methods of production or purification of viral material
- 2710/10152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10161 . . . . . Methods of inactivation or attenuation
- 2710/10162 . . . . . by genetic engineering
- 2710/10163 . . . . . by chemical treatment
- 2710/10164 . . . . . by serial passage
- 2710/10171 . . . . . Demonstrated *in vivo* effect
- 2710/10188 . . . . . for redistribution
- 2710/10211 . . . . . Aviadenovirus, e.g. fowl adenovirus A
- 2710/10221 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10222 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10223 . . . . . Virus like particles [VLP]
- 2710/10231 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10232 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10233 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10234 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10241 . . . . . Use of virus, viral particle or viral elements as a vector
- 2710/10242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10243 . . . . . viral genome or elements thereof as genetic vector
- 2710/10244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10245 . . . . . Special targeting system for viral vectors
- 2710/10251 . . . . . Methods of production or purification of viral material
- 2710/10252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10261 . . . . . Methods of inactivation or attenuation
- 2710/10262 . . . . . by genetic engineering
- 2710/10263 . . . . . by chemical treatment
- 2710/10264 . . . . . by serial passage
- 2710/10271 . . . . . Demonstrated *in vivo* effect
- 2710/10288 . . . . . for redistribution
- 2710/10311 . . . . . Mastadenovirus, e.g. human or simian adenoviruses
- 2710/10321 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10322 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10323 . . . . . Virus like particles [VLP]
- 2710/10331 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10332 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10333 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10334 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10341 . . . . . Use of virus, viral particle or viral elements as a vector
- 2710/10342 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10343 . . . . . viral genome or elements thereof as genetic vector
- 2710/10344 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10345 . . . . . Special targeting system for viral vectors
- 2710/10351 . . . . . Methods of production or purification of viral material
- 2710/10352 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10361 . . . . . Methods of inactivation or attenuation
- 2710/10362 . . . . . by genetic engineering
- 2710/10363 . . . . . by chemical treatment
- 2710/10364 . . . . . by serial passage
- 2710/10371 . . . . . Demonstrated *in vivo* effect
- 2710/10388 . . . . . for redistribution
- 2710/12011 . . . . . Asfarviridae
- 2710/12021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/12022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/12023 . . . . . Virus like particles [VLP]
- 2710/12031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/12032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/12033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/12034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/12041 . . . . . Use of virus, viral particle or viral elements as a vector
- 2710/12042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/12043 . . . . . viral genome or elements thereof as genetic vector
- 2710/12044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/12045 . . . . . Special targeting system for viral vectors
- 2710/12051 . . . . . Methods of production or purification of viral material

- 2710/12052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/12061 . . . Methods of inactivation or attenuation
- 2710/12062 . . . by genetic engineering
- 2710/12063 . . . by chemical treatment
- 2710/12064 . . . by serial passage
- 2710/12071 . . . Demonstrated in vivo effect
- 2710/12088 . . . for redistribution
- 2710/14011 . . Baculoviridae
- 2710/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/14023 . . . Virus like particles [VLP]
- 2710/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/14042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/14043 . . . viral genome or elements thereof as genetic vectore
- 2710/14044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/14045 . . . Special targeting system for viral vectors
- 2710/14051 . . . Methods of production or purification of viral material
- 2710/14052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/14061 . . . Methods of inactivation or attenuation
- 2710/14062 . . . by genetic engineering
- 2710/14063 . . . by chemical treatment
- 2710/14064 . . . by serial passage
- 2710/14071 . . . Demonstrated in vivo effect
- 2710/14088 . . . for redistribution
- 2710/14111 . . . Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- 2710/14121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/14122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/14123 . . . Virus like particles [VLP]
- 2710/14131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/14132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/14133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/14134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/14141 . . . Use of virus, viral particle or viral elements as a vector
- 2710/14142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/14143 . . . viral genome or elements thereof as genetic vector
- 2710/14144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/14145 . . . Special targeting system for viral vectors
- 2710/14151 . . . Methods of production or purification of viral material
- 2710/14152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/14161 . . . Methods of inactivation or attenuation
- 2710/14162 . . . by genetic engineering
- 2710/14163 . . . by chemical treatment
- 2710/14164 . . . by serial passage
- 2710/14171 . . . Demonstrated in vivo effect
- 2710/14188 . . . For redistribution
- 2710/16011 . . Herpesviridae
- 2710/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16023 . . . Virus like particles [VLP]
- 2710/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/16042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16043 . . . viral genome or elements thereof as genetic vector
- 2710/16044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16045 . . . Special targeting system for viral vectors
- 2710/16051 . . . Methods of production or purification of viral material
- 2710/16052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16061 . . . Methods of inactivation or attenuation
- 2710/16062 . . . by genetic engineering
- 2710/16063 . . . by chemical treatment
- 2710/16064 . . . by serial passage
- 2710/16071 . . . Demonstrated in vivo effect
- 2710/16088 . . . for redistribution
- 2710/16111 . . . Cytomegalovirus, e.g. human herpesvirus 5

- 2710/16121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16123 . . . . Virus like particles [VLP]
- 2710/16131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16141 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/16142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16143 . . . . . viral genome or elements thereof as genetic vector
- 2710/16144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16145 . . . . . Special targeting system for viral vectors
- 2710/16151 . . . . Methods of production or purification of viral material
- 2710/16152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16161 . . . . Methods of inactivation or attenuation
- 2710/16162 . . . . . by genetic engineering
- 2710/16163 . . . . . by chemical treatment
- 2710/16164 . . . . . by serial passage
- 2710/16171 . . . . Demonstrated *in vivo* effect
- 2710/16188 . . . . for redistribution
- 2710/16211 . . . Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- 2710/16221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16223 . . . . Virus like particles [VLP]
- 2710/16231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16241 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/16242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16243 . . . . . viral genome or elements thereof as genetic vector
- 2710/16244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16245 . . . . . Special targeting system for viral vectors
- 2710/16251 . . . . Methods of production or purification of viral material
- 2710/16252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16261 . . . . Methods of inactivation or attenuation
- 2710/16262 . . . . . by genetic engineering
- 2710/16263 . . . . . by chemical treatment
- 2710/16264 . . . . . by serial passage
- 2710/16271 . . . . Demonstrated *in vivo* effect
- 2710/16288 . . . . for redistribution
- 2710/16311 . . . Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- 2710/16321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16323 . . . . Virus like particles [VLP]
- 2710/16331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16341 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/16342 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16343 . . . . . viral genome or elements thereof as genetic vector
- 2710/16344 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16345 . . . . . Special targeting system for viral vectors
- 2710/16351 . . . . Methods of production or purification of viral material
- 2710/16352 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16361 . . . . Methods of inactivation or attenuation
- 2710/16362 . . . . . by genetic engineering
- 2710/16363 . . . . . by chemical treatment
- 2710/16364 . . . . . by serial passage
- 2710/16371 . . . . Demonstrated *in vivo* effect
- 2710/16388 . . . . for redistribution
- 2710/16411 . . . Rhadinovirus, e.g. human herpesvirus 8
- 2710/16421 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16422 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16423 . . . . Virus like particles [VLP]
- 2710/16431 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16432 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2710/16433 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16434 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16441 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/16442 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16443 . . . . . viral genome or elements thereof as genetic vector
- 2710/16444 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16445 . . . . . Special targeting system for viral vectors
- 2710/16451 . . . . Methods of production or purification of viral material
- 2710/16452 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16461 . . . . Methods of inactivation or attenuation
- 2710/16462 . . . . . by genetic engineering
- 2710/16463 . . . . . by chemical treatment
- 2710/16464 . . . . . by serial passage
- 2710/16471 . . . . Demonstrated in vivo effect
- 2710/16488 . . . . for redistribution
- 2710/16511 . . . Roseolovirus, e.g. human herpesvirus 6, 7
- 2710/16521 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16522 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16523 . . . . Virus like particles [VLP]
- 2710/16531 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16532 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16533 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16534 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral
- 2710/16541 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/16542 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16543 . . . . . viral genome or elements thereof as genetic vector
- 2710/16544 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16545 . . . . . Special targeting system for viral vectors
- 2710/16551 . . . . Methods of production or purification of viral material
- 2710/16552 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16561 . . . . Methods of inactivation or attenuation
- 2710/16562 . . . . . by genetic engineering
- 2710/16563 . . . . . by chemical treatment
- 2710/16564 . . . . . by serial passage
- 2710/16571 . . . . Demonstrated in vivo effect
- 2710/16588 . . . . for redistribution
- 2710/16611 . . . Simplexvirus, e.g. human herpesvirus 1, 2
- 2710/16621 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16622 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16623 . . . . Virus like particles [VLP]
- 2710/16631 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16632 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16633 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16634 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16641 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/16642 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16643 . . . . . viral genome or elements thereof as genetic vector
- 2710/16644 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16645 . . . . . Special targeting system for viral vectors
- 2710/16651 . . . . Methods of production or purification of viral material
- 2710/16652 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16661 . . . . Methods of inactivation or attenuation
- 2710/16662 . . . . . by genetic engineering
- 2710/16663 . . . . . by chemical treatment
- 2710/16664 . . . . . by serial passage
- 2710/16671 . . . . Demonstrated in vivo effect
- 2710/16688 . . . . for redistribution
- 2710/16711 . . . Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- 2710/16721 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16722 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16723 . . . . Virus like particles [VLP]
- 2710/16731 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16732 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16733 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16734 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16741 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/16742 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16743 . . . . . viral genome or elements thereof as genetic vector

- 2710/16744 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16745 . . . . Special targeting system for viral vectors
- 2710/16751 . . . . Methods of production or purification of viral material
- 2710/16752 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16761 . . . . Methods of inactivation or attenuation
- 2710/16762 . . . . by genetic engineering
- 2710/16763 . . . . by chemical treatment
- 2710/16764 . . . . by serial passage
- 2710/16771 . . . . Demonstrated *in vivo* effect
- 2710/16788 . . . . for redistribution
- 2710/18011 . . . . Nimaviridae
- 2710/18021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/18022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/18023 . . . . Virus like particles [VLP]
- 2710/18031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/18032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/18033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/18034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/18041 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/18042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/18043 . . . . viral genome or elements thereof as genetic vector
- 2710/18044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/18045 . . . . Special targeting system for viral vectors
- 2710/18051 . . . . Methods of production or purification of viral material
- 2710/18052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/18061 . . . . Methods of inactivation or attenuation
- 2710/18062 . . . . by genetic engineering
- 2710/18063 . . . . by chemical treatment
- 2710/18064 . . . . by serial passage
- 2710/18071 . . . . Demonstrated *in vivo* effect
- 2710/18088 . . . . for redistribution
- 2710/20011 . . . . Papillomaviridae
- 2710/20021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/20022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/20023 . . . . Virus like particles [VLP]
- 2710/20031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/20032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/20033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/20034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/20041 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/20042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/20043 . . . . viral genome or elements thereof as genetic vector
- 2710/20044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/20045 . . . . Special targeting system for viral vectors
- 2710/20051 . . . . Methods of production or purification of viral material
- 2710/20052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/20061 . . . . Methods of inactivation or attenuation
- 2710/20062 . . . . by genetic engineering
- 2710/20063 . . . . by chemical treatment
- 2710/20064 . . . . by serial passage
- 2710/20071 . . . . Demonstrated *in vivo* effect
- 2710/20088 . . . . for redistribution
- 2710/22011 . . . . Polyomaviridae, e.g. polyoma, SV40, JC
- 2710/22021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/22022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/22023 . . . . Virus like particles [VLP]
- 2710/22031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/22032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/22033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/22034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/22041 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/22042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/22043 . . . . viral genome or elements thereof as genetic vector
- 2710/22044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/22045 . . . . Special targeting system for viral vectors
- 2710/22051 . . . . Methods of production or purification of viral material
- 2710/22052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/22061 . . . . Methods of inactivation or attenuation
- 2710/22062 . . . . by genetic engineering
- 2710/22063 . . . . by chemical treatment
- 2710/22064 . . . . by serial passage
- 2710/22071 . . . . Demonstrated *in vivo* effect

- 2710/22088 . . . for redistribution
- 2710/24011 . . Poxviridae
- 2710/24021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/24022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/24023 . . . Virus like particles [VLP]
- 2710/24031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/24033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/24034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/24041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/24042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/24043 . . . . viral genome or elements thereof as genetic vector
- 2710/24044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/24045 . . . . Special targeting system for viral vectors
- 2710/24051 . . . Methods of production or purification of viral material
- 2710/24052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/24061 . . . Methods of inactivation or attenuation
- 2710/24062 . . . . by genetic engineering
- 2710/24063 . . . . by chemical treatment
- 2710/24064 . . . . by serial passage
- 2710/24071 . . . Demonstrated in vivo effect
- 2710/24088 . . . for redistribution
- 2710/24111 . . . Orthopoxvirus, e.g. vaccinia virus, variola
- 2710/24121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/24122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/24123 . . . . Virus like particles [VLP]
- 2710/24131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/24133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/24134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/24141 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/24142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/24143 . . . . . viral genome or elements thereof as genetic vector
- 2710/24144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/24145 . . . . . Special targeting system for viral vectors
- 2710/24151 . . . . Methods of production or purification of viral material
- 2710/24152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/24161 . . . . Methods of inactivation or attenuation
- 2710/24162 . . . . . by genetic engineering
- 2710/24163 . . . . . by chemical treatment
- 2710/24164 . . . . . by serial passage
- 2710/24171 . . . . Demonstrated in vivo effect
- 2710/24188 . . . . for redistribution
- 2710/24211 . . . Parapoxvirus, e.g. Orf virus
- 2710/24221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/24222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/24223 . . . . Virus like particles [VLP]
- 2710/24231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/24233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/24234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/24241 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/24242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/24243 . . . . . viral genome or elements thereof as genetic vector
- 2710/24244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/24245 . . . . . Special targeting system for viral vectors
- 2710/24251 . . . . Methods of production or purification of viral material
- 2710/24252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/24261 . . . . Methods of inactivation or attenuation
- 2710/24262 . . . . . by genetic engineering
- 2710/24263 . . . . . by chemical treatment
- 2710/24264 . . . . . by serial passage
- 2710/24271 . . . . Demonstrated in vivo effect
- 2710/24288 . . . . for redistribution
- 2720/00** **dsRNA viruses**
- 2720/00011 . Details
- 2720/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/00023 . . Virus like particles [VLP]
- 2720/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2720/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/00041 . . . Use of virus, viral particle or viral elements as a vector
- 2720/00042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/00043 . . . . viral genome or elements thereof as genetic vector
- 2720/00044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/00045 . . . . Special targeting system for viral vectors
- 2720/00051 . . . Methods of production or purification of viral material
- 2720/00052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/00061 . . . Methods of inactivation or attenuation
- 2720/00062 . . . . by genetic engineering
- 2720/00063 . . . . by chemical treatment
- 2720/00064 . . . . by serial passage
- 2720/00071 . . . Demonstrated in vivo effect
- 2720/00088 . . . for redistribution
- 2720/10011 . . . Birnaviridae
- 2720/10021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/10022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/10023 . . . . Virus like particles [VLP]
- 2720/10031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/10032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/10033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/10034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/10041 . . . . Use of virus, viral particle or viral elements as a vector
- 2720/10042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/10043 . . . . . viral genome or elements thereof as genetic vector
- 2720/10044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/10045 . . . . . Special targeting system for viral vectors
- 2720/10051 . . . . Methods of production or purification of viral material
- 2720/10052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/10061 . . . . Methods of inactivation or attenuation
- 2720/10062 . . . . . by genetic engineering
- 2720/10063 . . . . . by chemical treatment
- 2720/10064 . . . . . by serial passage
- 2720/10071 . . . . Demonstrated in vivo effect
- 2720/10088 . . . . for redistribution
- 2720/12011 . . . . Reoviridae
- 2720/12021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12023 . . . . . Virus like particles [VLP]
- 2720/12031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12041 . . . . . Use of virus, viral particle or viral elements as a vector
- 2720/12042 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12043 . . . . . . viral genome or elements thereof as genetic vector
- 2720/12044 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12045 . . . . . . Special targeting system for viral vectors
- 2720/12051 . . . . . Methods of production or purification of viral material
- 2720/12052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12061 . . . . . Methods of inactivation or attenuation
- 2720/12062 . . . . . . by genetic engineering
- 2720/12063 . . . . . . by chemical treatment
- 2720/12064 . . . . . . by serial passage
- 2720/12071 . . . . . Demonstrated in vivo effect
- 2720/12088 . . . . . for redistribution
- 2720/12111 . . . . . Orbivirus, e.g. bluetongue virus
- 2720/12121 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12122 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12123 . . . . . . Virus like particles [VLP]
- 2720/12131 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12132 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12133 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12134 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12141 . . . . . . Use of virus, viral particle or viral elements as a vector
- 2720/12142 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12143 . . . . . . . viral genome or elements thereof as genetic vector



- 2720/12144 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12145 . . . . Special targeting system for viral vectors
- 2720/12151 . . . . Methods of production or purification of viral material
- 2720/12152 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12161 . . . . Methods of inactivation or attenuation
- 2720/12162 . . . . by genetic engineering
- 2720/12163 . . . . by chemical treatment
- 2720/12164 . . . . by serial passage
- 2720/12171 . . . . Demonstrated *in vivo* effect
- 2720/12188 . . . . for redistribution
- 2720/12211 . . . . Orthoreovirus, e.g. mammalian orthoreovirus
- 2720/12221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12223 . . . . Virus like particles [VLP]
- 2720/12231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12241 . . . . Use of virus, viral particle or viral elements as a vector
- 2720/12242 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12243 . . . . viral genome or elements thereof as genetic vector
- 2720/12244 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12245 . . . . Special targeting system for viral vectors
- 2720/12251 . . . . Methods of production or purification of viral material
- 2720/12252 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12261 . . . . Methods of inactivation or attenuation
- 2720/12262 . . . . by genetic engineering
- 2720/12263 . . . . by chemical treatment
- 2720/12264 . . . . by serial passage
- 2720/12271 . . . . Demonstrated *in vivo* effect
- 2720/12288 . . . . for redistribution
- 2720/12311 . . . . Rotavirus, e.g. rotavirus A
- 2720/12321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12323 . . . . Virus like particles [VLP]
- 2720/12331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12341 . . . . Use of virus, viral particle or viral elements as a vector
- 2720/12342 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12343 . . . . viral genome or elements thereof as genetic vector
- 2720/12344 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12345 . . . . Special targeting system for viral vectors
- 2720/12351 . . . . Methods of production or purification of viral material
- 2720/12352 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12361 . . . . Methods of inactivation or attenuation
- 2720/12362 . . . . by genetic engineering
- 2720/12363 . . . . by chemical treatment
- 2720/12364 . . . . by serial passage
- 2720/12371 . . . . Demonstrated *in vivo* effect
- 2720/12388 . . . . for redistribution
- 2730/00** **Reverse transcribing DNA viruses**
- 2730/00011 . . . . Details
- 2730/00021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/00022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/00023 . . . . Virus like particles [VLP]
- 2730/00031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2730/00032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/00033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/00034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/00041 . . . . Use of virus, viral particle or viral elements as a vector
- 2730/00042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/00043 . . . . viral genome or elements thereof as genetic vector
- 2730/00044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/00045 . . . . Special targeting system for viral vectors
- 2730/00051 . . . . Methods of production or purification of viral material
- 2730/00052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/00061 . . . . Methods of inactivation or attenuation
- 2730/00062 . . . . by genetic engineering
- 2730/00063 . . . . by chemical treatment
- 2730/00064 . . . . by serial passage

- 2730/00071 . . . Demonstrated in vivo effect
- 2730/00088 . . . for redistribution
- 2730/10011 . . . Hepadnaviridae
- 2730/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/10023 . . . Virus like particles [VLP]
- 2730/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2730/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2730/10042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/10043 . . . viral genome or elements thereof as genetic vector
- 2730/10044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/10045 . . . Special targeting system for viral vectors
- 2730/10051 . . . Methods of production or purification of viral material
- 2730/10052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/10061 . . . Methods of inactivation or attenuation
- 2730/10062 . . . by genetic engineering
- 2730/10063 . . . by chemical treatment
- 2730/10064 . . . by serial passage
- 2730/10071 . . . Demonstrated in vivo effect
- 2730/10088 . . . for redistribution
- 2730/10111 . . . Orthohepadnavirus, e.g. hepatitis B virus
- 2730/10121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/10122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/10123 . . . Virus like particles [VLP]
- 2730/10131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2730/10132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/10133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/10134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/10141 . . . Use of virus, viral particle or viral elements as a vector
- 2730/10142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/10143 . . . viral genome or elements thereof as genetic vector
- 2730/10144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/10145 . . . Special targeting system for viral vectors
- 2730/10151 . . . Methods of production or purification of viral material
- 2730/10152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/10161 . . . Methods of inactivation or attenuation
- 2730/10162 . . . by genetic engineering
- 2730/10163 . . . by chemical treatment
- 2730/10164 . . . by serial passage
- 2730/10171 . . . Demonstrated in vivo effect
- 2730/10188 . . . for redistribution
- 2740/00** **Reverse transcribing RNA viruses**
- 2740/00011 . . . Details
- 2740/00021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/00022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/00023 . . . Virus like particles [VLP]
- 2740/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/00041 . . . Use of virus, viral particle or viral elements as a vector
- 2740/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/00043 . . . viral genome or elements thereof as genetic vector
- 2740/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/00045 . . . Special targeting system for viral vectors
- 2740/00051 . . . Methods of production or purification of viral material
- 2740/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/00061 . . . Methods of inactivation or attenuation
- 2740/00062 . . . by genetic engineering
- 2740/00063 . . . by chemical treatment
- 2740/00064 . . . by serial passage
- 2740/00071 . . . Demonstrated in vivo effect
- 2740/00088 . . . for redistribution
- 2740/10011 . . . Retroviridae
- 2740/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/10023 . . . Virus like particles [VLP]
- 2740/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2740/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2740/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/10043 . . . . viral genome or elements thereof as genetic vector
- 2740/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/10045 . . . . Special targeting system for viral vectors
- 2740/10051 . . . Methods of production or purification of viral material
- 2740/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/10061 . . . Methods of inactivation or attenuation
- 2740/10062 . . . . by genetic engineering
- 2740/10063 . . . . by chemical treatment
- 2740/10064 . . . . by serial passage
- 2740/10071 . . . Demonstrated in vivo effect
- 2740/10088 . . . for redistribution
- 2740/11011 . . . Alpharetrovirus, e.g. avian leucosis virus
- 2740/11021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/11022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/11023 . . . . Virus like particles [VLP]
- 2740/11031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/11032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/11033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/11034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/11041 . . . . Use of virus, viral particle or viral elements as a vector
- 2740/11042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/11043 . . . . . viral genome or elements thereof as genetic vector
- 2740/11044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/11045 . . . . . Special targeting system for viral vectors
- 2740/11051 . . . . Methods of production or purification of viral material
- 2740/11052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/11061 . . . . Methods of inactivation or attenuation
- 2740/11062 . . . . . by genetic engineering
- 2740/11063 . . . . . by chemical treatment
- 2740/11064 . . . . . by serial passage
- 2740/11071 . . . . Demonstrated in vivo effect
- 2740/11088 . . . . for redistribution
- 2740/12011 . . . Betaretrovirus, e.g. mouse mammary tumour virus
- 2740/12021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/12022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/12023 . . . . Virus like particles [VLP]
- 2740/12031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/12032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/12033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/12034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/12041 . . . . Use of virus, viral particle or viral elements as a vector
- 2740/12042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/12043 . . . . . viral genome or elements thereof as genetic vector
- 2740/12044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/12045 . . . . . Special targeting system for viral vectors
- 2740/12051 . . . . Methods of production or purification of viral material
- 2740/12052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/12061 . . . . Methods of inactivation or attenuation
- 2740/12062 . . . . . by genetic engineering
- 2740/12063 . . . . . by chemical treatment
- 2740/12064 . . . . . by serial passage
- 2740/12071 . . . . Demonstrated in vivo effect
- 2740/12088 . . . . for redistribution
- 2740/13011 . . . Gammaretrovirus, e.g. murine leukaemia virus
- 2740/13021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/13022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/13023 . . . . Virus like particles [VLP]
- 2740/13031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/13032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/13033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/13034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/13041 . . . . Use of virus, viral particle or viral elements as a vector
- 2740/13042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule

- 2740/13043 . . . . . viral genome or elements thereof as genetic vector
- 2740/13044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/13045 . . . . . Special targeting system for viral vectors
- 2740/13051 . . . . . Methods of production or purification of viral material
- 2740/13052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/13061 . . . . . Methods of inactivation or attenuation
- 2740/13062 . . . . . by genetic engineering
- 2740/13063 . . . . . by chemical treatment
- 2740/13064 . . . . . by serial passage
- 2740/13071 . . . . . Demonstrated in vivo effect
- 2740/13088 . . . . . for redistribution
- 2740/14011 . . . . . Deltaretrovirus, e.g. bovine leukaemia virus
- 2740/14021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/14022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/14023 . . . . . Virus like particles [VLP]
- 2740/14031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/14032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/14033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/14034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/14041 . . . . . Use of virus, viral particle or viral elements as a vector
- 2740/14042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/14043 . . . . . viral genome or elements thereof as genetic vector
- 2740/14044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/14045 . . . . . Special targeting system for viral vectors
- 2740/14051 . . . . . Methods of production or purification of viral material
- 2740/14052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/14061 . . . . . Methods of inactivation or attenuation
- 2740/14062 . . . . . by genetic engineering
- 2740/14063 . . . . . by chemical treatment
- 2740/14064 . . . . . by serial passage
- 2740/14071 . . . . . Demonstrated in vivo effect
- 2740/14088 . . . . . for redistribution
- 2740/15011 . . . . . Lentivirus, not HIV, e.g. FIV, SIV
- 2740/15021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/15022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/15023 . . . . . Virus like particles [VLP]
- 2740/15031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/15032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/15033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/15034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/15041 . . . . . Use of virus, viral particle or viral elements as a vector
- 2740/15042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/15043 . . . . . viral genome or elements thereof as genetic vector
- 2740/15044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/15045 . . . . . Special targeting system for viral vectors
- 2740/15051 . . . . . Methods of production or purification of viral material
- 2740/15052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/15061 . . . . . Methods of inactivation or attenuation
- 2740/15062 . . . . . by genetic engineering
- 2740/15063 . . . . . by chemical treatment
- 2740/15064 . . . . . by serial passage
- 2740/15071 . . . . . Demonstrated in vivo effect
- 2740/15088 . . . . . for redistribution
- 2740/16011 . . . . . Human Immunodeficiency Virus, HIV
- 2740/16021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/16022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16023 . . . . . Virus like particles [VLP]
- 2740/16031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/16032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/16033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/16034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16041 . . . . . Use of virus, viral particle or viral elements as a vector
- 2740/16042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/16043 . . . . . viral genome or elements thereof as genetic vector
- 2740/16044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/16045 . . . . . Special targeting system for viral vectors
- 2740/16051 . . . . . Methods of production or purification of viral material
- 2740/16052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/16061 . . . . . Methods of inactivation or attenuation
- 2740/16062 . . . . . by genetic engineering
- 2740/16063 . . . . . by chemical treatment

- 2740/16064 . . . . . by serial passage
- 2740/16071 . . . . . Demonstrated in vivo effect
- 2740/16088 . . . . . for redistribution
- 2740/16111 . . . . . concerning HIV env
- 2740/16122 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16134 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16171 . . . . . Demonstrated in vivo effect
- 2740/16188 . . . . . for redistribution
- 2740/16211 . . . . . concerning HIV gagpol
- 2740/16222 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16234 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16271 . . . . . Demonstrated in vivo effect
- 2740/16288 . . . . . for redistribution
- 2740/16311 . . . . . concerning HIV regulatory proteins
- 2740/16322 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16334 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16371 . . . . . Demonstrated in vivo effect
- 2740/16388 . . . . . for redistribution
- 2740/17011 . . . . . Spumavirus, e.g. chimpanzee foamy virus
- 2740/17021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/17022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/17023 . . . . . Virus like particles [VLP]
- 2740/17031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/17032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/17033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/17034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/17041 . . . . . Use of virus, viral particle or viral elements as a vector
- 2740/17042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/17043 . . . . . viral genome or elements thereof as genetic vector
- 2740/17044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/17045 . . . . . Special targeting system for viral vectors
- 2740/17051 . . . . . Methods of production or purification of viral material
- 2740/17052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/17061 . . . . . Methods of inactivation or attenuation
- 2740/17062 . . . . . by genetic engineering
- 2740/17063 . . . . . by chemical treatment
- 2740/17064 . . . . . by serial passage
- 2740/17071 . . . . . Demonstrated in vivo effect
- 2740/17088 . . . . . for redistribution
- 2750/00** **ssDNA viruses**
- 2750/00011 . . . . . Details
- 2750/00021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/00022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/00023 . . . . . Virus like particles [VLP]
- 2750/00031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/00032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/00033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/00034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/00041 . . . . . Use of virus, viral particle or viral elements as a vector
- 2750/00042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/00043 . . . . . viral genome or elements thereof as genetic vector
- 2750/00044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/00045 . . . . . Special targeting system for viral vectors
- 2750/00051 . . . . . Methods of production or purification of viral material
- 2750/00052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/00061 . . . . . Methods of inactivation or attenuation
- 2750/00062 . . . . . by genetic engineering
- 2750/00063 . . . . . by chemical treatment
- 2750/00064 . . . . . by serial passage
- 2750/00071 . . . . . Demonstrated in vivo effect
- 2750/00088 . . . . . for redistribution
- 2750/10011 . . . . . Circoviridae
- 2750/10021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/10022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/10023 . . . . . Virus like particles [VLP]
- 2750/10031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/10032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/10033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/10034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/10041 . . . . . Use of virus, viral particle or viral elements as a vector
- 2750/10042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule

- 2750/10043 . . . . viral genome or elements thereof as genetic vector
- 2750/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/10045 . . . . Special targeting system for viral vectors
- 2750/10051 . . . . Methods of production or purification of viral material
- 2750/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/10061 . . . . Methods of inactivation or attenuation
- 2750/10062 . . . . by genetic engineering
- 2750/10063 . . . . by chemical treatment
- 2750/10064 . . . . by serial passage
- 2750/10071 . . . . Demonstrated in vivo effect
- 2750/10088 . . . . for redistribution
- 2750/12011 . . . . Geminiviridae
- 2750/12021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/12022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/12023 . . . . Virus like particles [VLP]
- 2750/12031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/12032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/12033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/12034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/12041 . . . . Use of virus, viral particle or viral elements as a vector
- 2750/12042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/12043 . . . . viral genome or elements thereof as genetic vector
- 2750/12044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/12045 . . . . Special targeting system for viral vectors
- 2750/12051 . . . . Methods of production or purification of viral material
- 2750/12052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/12061 . . . . Methods of inactivation or attenuation
- 2750/12062 . . . . by genetic engineering
- 2750/12063 . . . . by chemical treatment
- 2750/12064 . . . . by serial passage
- 2750/12071 . . . . Demonstrated in vivo effect
- 2750/12088 . . . . for redistribution
- 2750/14011 . . . . Parvoviridae
- 2750/14021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14023 . . . . Virus like particles [VLP]
- 2750/14031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14041 . . . . Use of virus, viral particle or viral elements as a vector
- 2750/14042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14043 . . . . viral genome or elements thereof as genetic vector
- 2750/14044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14045 . . . . Special targeting system for viral vectors
- 2750/14051 . . . . Methods of production or purification of viral material
- 2750/14052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14061 . . . . Methods of inactivation or attenuation
- 2750/14062 . . . . by genetic engineering
- 2750/14063 . . . . by chemical treatment
- 2750/14064 . . . . by serial passage
- 2750/14071 . . . . Demonstrated in vivo effect
- 2750/14088 . . . . for redistribution
- 2750/14111 . . . . Dependovirus, e.g. adenoassociated viruses
- 2750/14121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14123 . . . . Virus like particles [VLP]
- 2750/14131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14141 . . . . Use of virus, viral particle or viral elements as a vector
- 2750/14142 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14143 . . . . viral genome or elements thereof as genetic vector
- 2750/14144 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14145 . . . . Special targeting system for viral vectors
- 2750/14151 . . . . Methods of production or purification of viral material
- 2750/14152 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14161 . . . . Methods of inactivation or attenuation
- 2750/14162 . . . . by genetic engineering
- 2750/14163 . . . . by chemical treatment

- 2750/14164 . . . . . by serial passage
- 2750/14171 . . . . . Demonstrated in vivo effect
- 2750/14188 . . . . . for redistribution
- 2750/14211 . . . . . Erythrovirus, e.g. B19 virus
- 2750/14221 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14222 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14223 . . . . . Virus like particles [VLP]
- 2750/14231 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14232 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14233 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14234 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14241 . . . . . Use of virus, viral particle or viral elements as a vector
- 2750/14242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14243 . . . . . viral genome or elements thereof as genetic vector
- 2750/14244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14245 . . . . . Special targeting system for viral vectors
- 2750/14251 . . . . . Methods of production or purification of viral material
- 2750/14252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14261 . . . . . Methods of inactivation or attenuation
- 2750/14262 . . . . . by genetic engineering
- 2750/14263 . . . . . by chemical treatment
- 2750/14264 . . . . . by serial passage
- 2750/14271 . . . . . Demonstrated in vivo effect
- 2750/14288 . . . . . for redistribution
- 2750/14311 . . . . . Parvovirus, e.g. minute virus of mice
- 2750/14321 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14322 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14323 . . . . . Virus like particles [VLP]
- 2750/14331 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14332 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14333 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14334 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14341 . . . . . Use of virus, viral particle or viral elements as a vector
- 2750/14342 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14343 . . . . . viral genome or elements thereof as genetic vector
- 2750/14344 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14345 . . . . . Special targeting system for viral vectors
- 2750/14351 . . . . . Methods of production or purification of viral material
- 2750/14352 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14361 . . . . . Methods of inactivation or attenuation
- 2750/14362 . . . . . by genetic engineering
- 2750/14363 . . . . . by chemical treatment
- 2750/14364 . . . . . by serial passage
- 2750/14371 . . . . . Demonstrated in vivo effect
- 2750/14388 . . . . . for redistribution
- 2760/00** **ssRNA viruses negative-sense**
- 2760/00011 . . . . . Details
- 2760/00021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/00022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/00023 . . . . . Virus like particles [VLP]
- 2760/00031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/00032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/00033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/00034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/00041 . . . . . Use of virus, viral particle or viral elements as a vector
- 2760/00042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/00043 . . . . . viral genome or elements thereof as genetic vector
- 2760/00044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/00045 . . . . . Special targeting system for viral vectors
- 2760/00051 . . . . . Methods of production or purification of viral material
- 2760/00052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/00061 . . . . . Methods of inactivation or attenuation
- 2760/00062 . . . . . by genetic engineering
- 2760/00063 . . . . . by chemical treatment
- 2760/00064 . . . . . by serial passage
- 2760/00071 . . . . . Demonstrated in vivo effect
- 2760/00088 . . . . . for redistribution
- 2760/10011 . . . . . Arenaviridae
- 2760/10021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/10022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/10023 . . . . . Virus like particles [VLP]
- 2760/10031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2760/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/10043 . . . . viral genome or elements thereof as genetic vector
- 2760/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/10045 . . . . Special targeting system for viral vectors
- 2760/10051 . . . Methods of production or purification of viral material
- 2760/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/10061 . . . Methods of inactivation or attenuation
- 2760/10062 . . . . by genetic engineering
- 2760/10063 . . . . by chemical treatment
- 2760/10064 . . . . by serial passage
- 2760/10071 . . . Demonstrated in vivo effect
- 2760/10088 . . . for redistribution
- 2760/10111 . . . Deltavirus, e.g. hepatitis delta virus
- 2760/10121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/10122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/10123 . . . . Virus like particles [VLP]
- 2760/10131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/10132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/10134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/10141 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/10142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/10143 . . . . . viral genome or elements thereof as genetic vector
- 2760/10144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/10145 . . . . . Special targeting system for viral vectors
- 2760/10151 . . . . Methods of production or purification of viral material
- 2760/10152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/10161 . . . . Methods of inactivation or attenuation
- 2760/10162 . . . . . by genetic engineering
- 2760/10163 . . . . . by chemical treatment
- 2760/10164 . . . . . by serial passage
- 2760/10171 . . . . Demonstrated in vivo effect
- 2760/10188 . . . . for redistribution
- 2760/12011 . . . Bunyaviridae
- 2760/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12023 . . . Virus like particles [VLP]
- 2760/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/12042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12043 . . . . viral genome or elements thereof as genetic vector
- 2760/12044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12045 . . . . Special targeting system for viral vectors
- 2760/12051 . . . Methods of production or purification of viral material
- 2760/12052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12061 . . . Methods of inactivation or attenuation
- 2760/12062 . . . . by genetic engineering
- 2760/12063 . . . . by chemical treatment
- 2760/12064 . . . . by serial passage
- 2760/12071 . . . Demonstrated in vivo effect
- 2760/12088 . . . for redistribution
- 2760/12111 . . . Hantavirus, e.g. Hantaan virus
- 2760/12121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12123 . . . . Virus like particles [VLP]
- 2760/12131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12141 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/12142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12143 . . . . . viral genome or elements thereof as genetic vector



- 2760/12144 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12145 . . . . Special targeting system for viral vectors
- 2760/12151 . . . . Methods of production or purification of viral material
- 2760/12152 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12161 . . . . Methods of inactivation or attenuation
- 2760/12162 . . . . by genetic engineering
- 2760/12163 . . . . by chemical treatment
- 2760/12164 . . . . by serial passage
- 2760/12171 . . . . Demonstrated *in vivo* effect
- 2760/12188 . . . . for redistribution
- 2760/12211 . . . Phlebovirus, e.g. Rift Valley fever virus
- 2760/12221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12223 . . . . Virus like particles [VLP]
- 2760/12231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12241 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/12242 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12243 . . . . viral genome or elements thereof as genetic vector
- 2760/12244 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12245 . . . . Special targeting system for viral vectors
- 2760/12251 . . . . Methods of production or purification of viral material
- 2760/12252 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12261 . . . . Methods of inactivation or attenuation
- 2760/12262 . . . . by genetic engineering
- 2760/12263 . . . . by chemical treatment
- 2760/12264 . . . . by serial passage
- 2760/12271 . . . . Demonstrated *in vivo* effect
- 2760/12288 . . . . for redistribution
- 2760/14011 . . Filoviridae
- 2760/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14023 . . . Virus like particles [VLP]
- 2760/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/14042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14043 . . . . viral genome or elements thereof as genetic vector
- 2760/14044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14045 . . . . Special targeting system for viral vectors
- 2760/14051 . . . . Methods of production or purification of viral material
- 2760/14052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14061 . . . . Methods of inactivation or attenuation
- 2760/14062 . . . . by genetic engineering
- 2760/14063 . . . . by chemical treatment
- 2760/14064 . . . . by serial passage
- 2760/14071 . . . . Demonstrated *in vivo* effect
- 2760/14088 . . . . for redistribution
- 2760/14111 . . . Ebolavirus, e.g. Zaire ebolavirus
- 2760/14121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14123 . . . . Virus like particles [VLP]
- 2760/14131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14141 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/14142 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14143 . . . . viral genome or elements thereof as genetic vector
- 2760/14144 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14145 . . . . Special targeting system for viral vectors
- 2760/14151 . . . . Methods of production or purification of viral material
- 2760/14152 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14161 . . . . Methods of inactivation or attenuation
- 2760/14162 . . . . by genetic engineering
- 2760/14163 . . . . by chemical treatment
- 2760/14164 . . . . by serial passage
- 2760/14171 . . . . Demonstrated *in vivo* effect

- 2760/14188 . . . . for redistribution
- 2760/14211 . . . Marburgvirus, e.g. lake Victoria marburgvirus
- 2760/14221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14223 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14241 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/14242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14243 . . . . . viral genome or elements thereof as genetic vector
- 2760/14244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14245 . . . . . Special targeting system for viral vectors
- 2760/14251 . . . . Methods of production or purification of viral material
- 2760/14252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14261 . . . . Methods of inactivation or attenuation
- 2760/14262 . . . . . by genetic engineering
- 2760/14263 . . . . . by chemical treatment
- 2760/14264 . . . . . by serial passage
- 2760/14271 . . . . Demonstrated *in vivo* effect
- 2760/14288 . . . . for redistribution
- 2760/16011 . . . Orthomyxoviridae
- 2760/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16023 . . . Virus like particles [VLP]
- 2760/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/16042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16043 . . . . viral genome or elements thereof as genetic vector
- 2760/16044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16045 . . . . Special targeting system for viral vectors
- 2760/16051 . . . Methods of production or purification of viral material
- 2760/16052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16061 . . . Methods of inactivation or attenuation
- 2760/16062 . . . . by genetic engineering
- 2760/16063 . . . . by chemical treatment
- 2760/16064 . . . . by serial passage
- 2760/16071 . . . Demonstrated *in vivo* effect
- 2760/16088 . . . for redistribution
- 2760/16111 . . . Influenzavirus A, i.e. influenza A virus
- 2760/16121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16123 . . . . Virus like particles [VLP]
- 2760/16131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16141 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/16142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16143 . . . . . viral genome or elements thereof as genetic vector
- 2760/16144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16145 . . . . . Special targeting system for viral vectors
- 2760/16151 . . . . Methods of production or purification of viral material
- 2760/16152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16161 . . . . Methods of inactivation or attenuation
- 2760/16162 . . . . . by genetic engineering
- 2760/16163 . . . . . by chemical treatment
- 2760/16164 . . . . . by serial passage
- 2760/16171 . . . . Demonstrated *in vivo* effect
- 2760/16188 . . . . for redistribution
- 2760/16211 . . . Influenzavirus B, i.e. influenza B virus
- 2760/16221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16223 . . . . Virus like particles [VLP]
- 2760/16231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2760/16233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16241 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/16242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16243 . . . . . viral genome or elements thereof as genetic vector
- 2760/16244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16245 . . . . . Special targeting system for viral vectors
- 2760/16251 . . . . Methods of production or purification of viral material
- 2760/16252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16261 . . . . Methods of inactivation or attenuation
- 2760/16262 . . . . . by genetic engineering
- 2760/16263 . . . . . by chemical treatment
- 2760/16264 . . . . . by serial passage
- 2760/16271 . . . . Demonstrated in vivo effect
- 2760/16288 . . . . for redistribution
- 2760/16311 . . . Influenzavirus C, i.e. influenza C virus
- 2760/16321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16323 . . . . Virus like particles [VLP]
- 2760/16331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16341 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/16342 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16343 . . . . . viral genome or elements thereof as genetic vector
- 2760/16344 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16345 . . . . . Special targeting system for viral vectors
- 2760/16351 . . . . Methods of production or purification of viral material
- 2760/16352 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16361 . . . . Methods of inactivation or attenuation
- 2760/16362 . . . . . by genetic engineering
- 2760/16363 . . . . . by chemical treatment
- 2760/16364 . . . . . by serial passage
- 2760/16371 . . . . Demonstrated in vivo effect
- 2760/16388 . . . . for redistribution
- 2760/18011 . . Paramyxoviridae
- 2760/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18023 . . . Virus like particles [VLP]
- 2760/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/18042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18043 . . . . viral genome or elements thereof as genetic vector
- 2760/18044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18045 . . . . Special targeting system for viral vectors
- 2760/18051 . . . Methods of production or purification of viral material
- 2760/18052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18061 . . . Methods of inactivation or attenuation
- 2760/18062 . . . . by genetic engineering
- 2760/18063 . . . . by chemical treatment
- 2760/18064 . . . . by serial passage
- 2760/18071 . . . Demonstrated in vivo effect
- 2760/18088 . . . for redistribution
- 2760/18111 . . . Avulavirus, e.g. Newcastle disease virus
- 2760/18121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18123 . . . . Virus like particles [VLP]
- 2760/18131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18141 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18143 . . . . . viral genome or elements thereof as genetic vector

- 2760/18144 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18145 . . . . Special targeting system for viral vectors
- 2760/18151 . . . . Methods of production or purification of viral material
- 2760/18152 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18161 . . . . Methods of inactivation or attenuation
- 2760/18162 . . . . by genetic engineering
- 2760/18163 . . . . by chemical treatment
- 2760/18164 . . . . by serial passage
- 2760/18171 . . . . Demonstrated *in vivo* effect
- 2760/18188 . . . . for redistribution
- 2760/18211 . . . Henipavirus, e.g. hendra virus
- 2760/18221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18223 . . . . Virus like particles [VLP]
- 2760/18231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18241 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18242 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18243 . . . . viral genome or elements thereof as genetic vector
- 2760/18244 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18245 . . . . Special targeting system for viral vectors
- 2760/18251 . . . . Methods of production or purification of viral material
- 2760/18252 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18261 . . . . Methods of inactivation or attenuation
- 2760/18262 . . . . by genetic engineering
- 2760/18263 . . . . by chemical treatment
- 2760/18264 . . . . by serial passage
- 2760/18271 . . . . Demonstrated *in vivo* effect
- 2760/18288 . . . . for redistribution
- 2760/18311 . . . Metapneumovirus, e.g. avian pneumovirus
- 2760/18321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18323 . . . . Virus like particles [VLP]
- 2760/18331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18341 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18342 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18343 . . . . viral genome or elements thereof as genetic vector
- 2760/18344 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18345 . . . . Special targeting system for viral vectors
- 2760/18351 . . . . Methods of production or purification of viral material
- 2760/18352 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18361 . . . . Methods of inactivation or attenuation
- 2760/18362 . . . . by genetic engineering
- 2760/18363 . . . . by chemical treatment
- 2760/18364 . . . . by serial passage
- 2760/18371 . . . . Demonstrated *in vivo* effect
- 2760/18388 . . . . for redistribution
- 2760/18411 . . . Morbillivirus, e.g. Measles virus, canine distemper
- 2760/18421 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18422 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18423 . . . . Virus like particles [VLP]
- 2760/18431 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18432 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18433 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18434 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18441 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18442 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18443 . . . . viral genome or elements thereof as genetic vector
- 2760/18444 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18445 . . . . Special targeting system for viral vectors
- 2760/18451 . . . . Methods of production or purification of viral material
- 2760/18452 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18461 . . . . Methods of inactivation or attenuation
- 2760/18462 . . . . by genetic engineering
- 2760/18463 . . . . by chemical treatment
- 2760/18464 . . . . by serial passage

- 2760/18471 . . . . Demonstrated in vivo effect
- 2760/18488 . . . . For redistribution
- 2760/18511 . . . . Pneumovirus, e.g. human respiratory syncytial virus
- 2760/18521 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18522 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18523 . . . . Virus like particles [VLP]
- 2760/18531 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18532 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18533 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18534 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18541 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18542 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18543 . . . . . viral genome or elements thereof as genetic vector
- 2760/18544 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18545 . . . . . Special targeting system for viral vectors
- 2760/18551 . . . . Methods of production or purification of viral material
- 2760/18552 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18561 . . . . Methods of inactivation or attenuation
- 2760/18562 . . . . . by genetic engineering
- 2760/18563 . . . . . by chemical treatment
- 2760/18564 . . . . . by serial passage
- 2760/18571 . . . . Demonstrated in vivo effect
- 2760/18588 . . . . for redistribution
- 2760/18611 . . . . Respirovirus, e.g. Bovine, human parainfluenza 1,3
- 2760/18621 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18622 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18623 . . . . Virus like particles [VLP]
- 2760/18631 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18632 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18633 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18634 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18641 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18642 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18643 . . . . . viral genome or elements thereof as genetic vector
- 2760/18644 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18645 . . . . . Special targeting system for viral vectors
- 2760/18651 . . . . Methods of production or purification of viral material
- 2760/18652 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18661 . . . . Methods of inactivation or attenuation
- 2760/18662 . . . . . by genetic engineering
- 2760/18663 . . . . . by chemical treatment
- 2760/18664 . . . . . by serial passage
- 2760/18671 . . . . Demonstrated in vivo effect
- 2760/18688 . . . . for redistribution
- 2760/18711 . . . . Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- 2760/18721 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18722 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18723 . . . . Virus like particles [VLP]
- 2760/18731 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18732 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18733 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18734 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18741 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18742 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18743 . . . . . viral genome or elements thereof as genetic vector
- 2760/18744 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18745 . . . . . Special targeting system for viral vectors
- 2760/18751 . . . . Methods of production or purification of viral material
- 2760/18752 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18761 . . . . Methods of inactivation or attenuation
- 2760/18762 . . . . . by genetic engineering
- 2760/18763 . . . . . by chemical treatment
- 2760/18764 . . . . . by serial passage
- 2760/18771 . . . . Demonstrated in vivo effect
- 2760/18788 . . . . for redistribution
- 2760/18811 . . . . Sendai virus
- 2760/18821 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18822 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18823 . . . . Virus like particles [VLP]

- 2760/18831 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18832 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18833 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18834 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18841 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18842 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18843 . . . . . viral genome or elements thereof as genetic vector
- 2760/18845 . . . . . Special targeting system for viral vectors
- 2760/18851 . . . . Methods of production or purification of viral material
- 2760/18852 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18861 . . . . Methods of inactivation or attenuation
- 2760/18862 . . . . . by genetic engineering
- 2760/18863 . . . . . by chemical treatment
- 2760/18864 . . . . . by serial passage
- 2760/18871 . . . . Demonstrated *in vivo* effect
- 2760/18888 . . . . for redistribution
- 2760/20011 . . Rhabdoviridae
- 2760/20021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/20022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/20023 . . . Virus like particles [VLP]
- 2760/20031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/20032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/20033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/20041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/20042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/20043 . . . . viral genome or elements thereof as genetic vector
- 2760/20044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/20045 . . . . Special targeting system for viral vectors
- 2760/20051 . . . Methods of production or purification of viral material
- 2760/20052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/20061 . . . Methods of inactivation or attenuation
- 2760/20062 . . . . by genetic engineering
- 2760/20063 . . . . by chemical treatment
- 2760/20064 . . . . by serial passage
- 2760/20071 . . . Demonstrated *in vivo* effect
- 2760/20088 . . . for redistribution
- 2760/20111 . . . Lyssavirus, e.g. rabies virus
- 2760/20121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/20122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/20123 . . . . Virus like particles [VLP]
- 2760/20131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/20132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/20133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/20134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/20141 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/20142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/20143 . . . . . viral genome or elements thereof as genetic vector
- 2760/20144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/20145 . . . . . Special targeting system for viral vectors
- 2760/20151 . . . . Methods of production or purification of viral material
- 2760/20152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/20161 . . . . Methods of inactivation or attenuation
- 2760/20162 . . . . . by genetic engineering
- 2760/20163 . . . . . by chemical treatment
- 2760/20164 . . . . . by serial passage
- 2760/20171 . . . . Demonstrated *in vivo* effect
- 2760/20188 . . . . for redistribution
- 2760/20211 . . . Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- 2760/20221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/20222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/20223 . . . . Virus like particles [VLP]
- 2760/20231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/20232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/20233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/20234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/20241 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/20242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/20243 . . . . . viral genome or elements thereof as genetic vector

- 2760/20244 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/20245 . . . . Special targeting system for viral vectors
- 2760/20251 . . . . Methods of production or purification of viral material
- 2760/20252 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/20261 . . . . Methods of inactivation or attenuation
- 2760/20262 . . . . by genetic engineering
- 2760/20263 . . . . by chemical treatment
- 2760/20264 . . . . by serial passage
- 2760/20271 . . . . Demonstrated *in vivo* effect
- 2760/20288 . . . . for redistribution
- 2770/00** **ssRNA viruses positive-sense**
- 2770/00011 . Details
- 2770/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/00023 . . Virus like particles [VLP]
- 2770/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/00041 . . Use of virus, viral particle or viral elements as a vector
- 2770/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/00043 . . . viral genome or elements thereof as genetic vector
- 2770/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/00045 . . . Special targeting system for viral vectors
- 2770/00051 . . Methods of production or purification of viral material
- 2770/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/00061 . . Methods of inactivation or attenuation
- 2770/00062 . . . by genetic engineering
- 2770/00063 . . . by chemical treatment
- 2770/00064 . . . by serial passage
- 2770/00071 . . Demonstrated *in vivo* effect
- 2770/00088 . . for redistribution
- 2770/10011 . . Arteriviridae
- 2770/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/10023 . . . Virus like particles [VLP]
- 2770/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/10043 . . . . viral genome or elements thereof as genetic vector
- 2770/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/10045 . . . . Special targeting system for viral vectors
- 2770/10051 . . . Methods of production or purification of viral material
- 2770/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/10061 . . . Methods of inactivation or attenuation
- 2770/10062 . . . . by genetic engineering
- 2770/10063 . . . . by chemical treatment
- 2770/10064 . . . . by serial passage
- 2770/10071 . . . Demonstrated *in vivo* effect
- 2770/10088 . . . for redistribution
- 2770/12011 . . Astroviridae
- 2770/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/12023 . . . Virus like particles [VLP]
- 2770/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/12042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/12043 . . . . viral genome or elements thereof as genetic vector
- 2770/12044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/12045 . . . . Special targeting system for viral vectors
- 2770/12051 . . . Methods of production or purification of viral material
- 2770/12052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/12061 . . . Methods of inactivation or attenuation
- 2770/12062 . . . . by genetic engineering
- 2770/12063 . . . . by chemical treatment

- 2770/12064 . . . . by serial passage
- 2770/12071 . . . Demonstrated in vivo effect
- 2770/12088 . . . for redistribution
- 2770/14011 . . Bromoviridae
- 2770/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/14023 . . . Virus like particles [VLP]
- 2770/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/14042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/14043 . . . . viral genome or elements thereof as genetic vector
- 2770/14044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/14045 . . . . Special targeting system for viral vectors
- 2770/14051 . . . Methods of production or purification of viral material
- 2770/14052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/14061 . . . Methods of inactivation or attenuation
- 2770/14062 . . . . by genetic engineering
- 2770/14063 . . . . by chemical treatment
- 2770/14064 . . . . by serial passage
- 2770/14071 . . . Demonstrated in vivo effect
- 2770/14088 . . . for redistribution
- 2770/16011 . . Caliciviridae
- 2770/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/16023 . . . Virus like particles [VLP]
- 2770/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/16042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/16043 . . . . viral genome or elements thereof as genetic vector
- 2770/16044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/16045 . . . . Special targeting system for viral vectors
- 2770/16051 . . . Methods of production or purification of viral material
- 2770/16052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/16061 . . . Methods of inactivation or attenuation
- 2770/16062 . . . . by genetic engineering
- 2770/16063 . . . . by chemical treatment
- 2770/16064 . . . . by serial passage
- 2770/16071 . . . Demonstrated in vivo effect
- 2770/16088 . . . for redistribution
- 2770/18011 . . Comoviridae
- 2770/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/18023 . . . Virus like particles [VLP]
- 2770/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/18042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/18043 . . . . viral genome or elements thereof as genetic vector
- 2770/18044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/18045 . . . . Special targeting system for viral vectors
- 2770/18051 . . . Methods of production or purification of viral material
- 2770/18052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/18061 . . . Methods of inactivation or attenuation
- 2770/18062 . . . . by genetic engineering
- 2770/18063 . . . . by chemical treatment
- 2770/18064 . . . . by serial passage
- 2770/18071 . . . Demonstrated in vivo effect
- 2770/18088 . . . for redistribution
- 2770/20011 . . Coronaviridae
- 2770/20021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/20022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/20023 . . . Virus like particles [VLP]
- 2770/20031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/20032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent



- 2770/20033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/20041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/20042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/20043 . . . . viral genome or elements thereof as genetic vector
- 2770/20044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/20045 . . . . Special targeting system for viral vectors
- 2770/20051 . . . Methods of production or purification of viral material
- 2770/20052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/20061 . . . Methods of inactivation or attenuation
- 2770/20062 . . . . by genetic engineering
- 2770/20063 . . . . by chemical treatment
- 2770/20064 . . . . by serial passage
- 2770/20071 . . . Demonstrated in vivo effect
- 2770/20088 . . . for redistribution
- 2770/22011 . . Dicistroviridae
- 2770/22021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/22022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/22023 . . . Virus like particles [VLP]
- 2770/22031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/22032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/22033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/22034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/22041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/22042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/22043 . . . . viral genome or elements thereof as genetic vector
- 2770/22044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/22045 . . . . Special targeting system for viral vectors
- 2770/22051 . . . Methods of production or purification of viral material
- 2770/22052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/22061 . . . Methods of inactivation or attenuation
- 2770/22062 . . . . by genetic engineering
- 2770/22063 . . . . by chemical treatment
- 2770/22064 . . . . by serial passage
- 2770/22071 . . . Demonstrated in vivo effect
- 2770/22088 . . . for redistribution
- 2770/24011 . . Flaviviridae
- 2770/24021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24023 . . . Virus like particles [VLP]
- 2770/24031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/24042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24043 . . . . viral genome or elements thereof as genetic vector
- 2770/24044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24045 . . . . Special targeting system for viral vectors
- 2770/24051 . . . Methods of production or purification of viral material
- 2770/24052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24061 . . . Methods of inactivation or attenuation
- 2770/24062 . . . . by genetic engineering
- 2770/24063 . . . . by chemical treatment
- 2770/24064 . . . . by serial passage
- 2770/24071 . . . Demonstrated in vivo effect
- 2770/24088 . . . for redistribution
- 2770/24111 . . . Flavivirus, e.g. yellow fever virus, dengue, JEV
- 2770/24121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24123 . . . . Virus like particles [VLP]
- 2770/24131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24141 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/24142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24143 . . . . . viral genome or elements thereof as genetic vector

- 2770/24144 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24145 . . . . Special targeting system for viral vectors
- 2770/24151 . . . . Methods of production or purification of viral material
- 2770/24152 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24161 . . . . Methods of inactivation or attenuation
- 2770/24162 . . . . by genetic engineering
- 2770/24163 . . . . by chemical treatment
- 2770/24164 . . . . by serial passage
- 2770/24171 . . . . Demonstrated *in vivo* effect
- 2770/24188 . . . . for redistribution
- 2770/24211 . . . Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- 2770/24221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24223 . . . . Virus like particles [VLP]
- 2770/24231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24241 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/24242 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24243 . . . . viral genome or elements thereof as genetic vector
- 2770/24244 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24245 . . . . Special targeting system for viral vectors
- 2770/24251 . . . . Methods of production or purification of viral material
- 2770/24252 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24261 . . . . Methods of inactivation or attenuation
- 2770/24262 . . . . by genetic engineering
- 2770/24263 . . . . by chemical treatment
- 2770/24264 . . . . by serial passage
- 2770/24271 . . . . Demonstrated *in vivo* effect
- 2770/24288 . . . . for redistribution
- 2770/24311 . . . Pestivirus, e.g. bovine viral diarrhea virus
- 2770/24321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24323 . . . . Virus like particles [VLP]
- 2770/24331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24341 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/24342 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24343 . . . . viral genome or elements thereof as genetic vector
- 2770/24344 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24345 . . . . Special targeting system for viral vectors
- 2770/24351 . . . . Methods of production or purification of viral material
- 2770/24352 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24361 . . . . Methods of inactivation or attenuation
- 2770/24362 . . . . by genetic engineering
- 2770/24363 . . . . by chemical treatment
- 2770/24364 . . . . by serial passage
- 2770/24371 . . . . Demonstrated *in vivo* effect
- 2770/24388 . . . . for redistribution
- 2770/26011 . . . Flexiviridae
- 2770/26021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/26022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/26023 . . . Virus like particles [VLP]
- 2770/26031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/26032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/26033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/26034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/26041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/26042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/26043 . . . viral genome or elements thereof as genetic vector
- 2770/26044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/26045 . . . Special targeting system for viral vectors
- 2770/26051 . . . Methods of production or purification of viral material
- 2770/26052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/26061 . . . Methods of inactivation or attenuation
- 2770/26062 . . . by genetic engineering
- 2770/26063 . . . by chemical treatment

- 2770/26064 . . . . by serial passage
- 2770/26071 . . . Demonstrated in vivo effect
- 2770/26088 . . . for redistribution
- 2770/28011 . . Hepeviridae
- 2770/28021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28023 . . . Virus like particles [VLP]
- 2770/28031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/28042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28043 . . . . viral genome or elements thereof as genetic vector
- 2770/28044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28045 . . . . Special targeting system for viral vectors
- 2770/28051 . . . Methods of production or purification of viral material
- 2770/28052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28061 . . . Methods of inactivation or attenuation
- 2770/28062 . . . . by genetic engineering
- 2770/28063 . . . . by chemical treatment
- 2770/28064 . . . . by serial passage
- 2770/28071 . . . Demonstrated in vivo effect
- 2770/28088 . . . for redistribution
- 2770/28111 . . . Hepevirus, e.g. hepatitis E virus
- 2770/28121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28123 . . . . Virus like particles [VLP]
- 2770/28131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28141 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/28142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28143 . . . . . viral genome or elements thereof as genetic vector
- 2770/28144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28145 . . . . . Special targeting system for viral vectors
- 2770/28151 . . . . Methods of production or purification of viral material
- 2770/28152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28161 . . . . Methods of inactivation or attenuation
- 2770/28162 . . . . . by genetic engineering
- 2770/28163 . . . . . by chemical treatment
- 2770/28164 . . . . . by serial passage
- 2770/28171 . . . . Demonstrated in vivo effect
- 2770/28188 . . . . for redistribution
- 2770/30011 . . Nodaviridae
- 2770/30021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/30022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/30023 . . . Virus like particles [VLP]
- 2770/30031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/30032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/30033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/30034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/30041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/30042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/30043 . . . . viral genome or elements thereof as genetic vector
- 2770/30044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/30045 . . . . Special targeting system for viral vectors
- 2770/30051 . . . Methods of production or purification of viral material
- 2770/30052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/30061 . . . Methods of inactivation or attenuation
- 2770/30062 . . . . by genetic engineering
- 2770/30063 . . . . by chemical treatment
- 2770/30064 . . . . by serial passage
- 2770/30071 . . . Demonstrated in vivo effect
- 2770/30088 . . . for redistribution
- 2770/32011 . . Picornaviridae
- 2770/32021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32023 . . . Virus like particles [VLP]
- 2770/32031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2770/32033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/32042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32043 . . . . viral genome or elements thereof as genetic vector
- 2770/32044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32045 . . . . Special targeting system for viral vectors
- 2770/32051 . . . Methods of production or purification of viral material
- 2770/32052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32061 . . . Methods of inactivation or attenuation
- 2770/32062 . . . . by genetic engineering
- 2770/32063 . . . . by chemical treatment
- 2770/32064 . . . . by serial passage
- 2770/32071 . . . Demonstrated *in vivo* effect
- 2770/32088 . . . for redistribution
- 2770/32111 . . . Aphthovirus, e.g. footandmouth disease virus
- 2770/32121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32123 . . . . Virus like particles [VLP]
- 2770/32131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32141 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32143 . . . . . viral genome or elements thereof as genetic vector
- 2770/32144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32145 . . . . . Special targeting system for viral vectors
- 2770/32151 . . . . Methods of production or purification of viral material
- 2770/32152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32161 . . . . Methods of inactivation or attenuation
- 2770/32162 . . . . . by genetic engineering
- 2770/32163 . . . . . by chemical treatment
- 2770/32164 . . . . . by serial passage
- 2770/32171 . . . . Demonstrated *in vivo* effect
- 2770/32188 . . . . for redistribution
- 2770/32211 . . . . Cardiovirus, e.g. encephalomyocarditis virus
- 2770/32221 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32222 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32223 . . . . . Virus like particles [VLP]
- 2770/32231 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32232 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32233 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32234 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32241 . . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32242 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32243 . . . . . . viral genome or elements thereof as genetic vector
- 2770/32244 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32245 . . . . . . Special targeting system for viral vectors
- 2770/32251 . . . . . Methods of production or purification of viral material
- 2770/32252 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32261 . . . . . Methods of inactivation or attenuation
- 2770/32262 . . . . . . by genetic engineering
- 2770/32263 . . . . . . by chemical treatment
- 2770/32264 . . . . . . by serial passage
- 2770/32271 . . . . . Demonstrated *in vivo* effect
- 2770/32288 . . . . . for redistribution
- 2770/32311 . . . . Enterovirus
- 2770/32321 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32322 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32323 . . . . . Virus like particles [VLP]
- 2770/32331 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32332 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32333 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32334 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32341 . . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32342 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32343 . . . . . . viral genome or elements thereof as genetic vector

- 2770/32344 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32345 . . . . Special targeting system for viral vectors
- 2770/32351 . . . . Methods of production or purification of viral material
- 2770/32352 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32361 . . . . Methods of inactivation or attenuation
- 2770/32362 . . . . by genetic engineering
- 2770/32363 . . . . by chemical treatment
- 2770/32364 . . . . by serial passage
- 2770/32371 . . . . Demonstrated *in vivo* effect
- 2770/32388 . . . . for redistribution
- 2770/32411 . . . . Hepatovirus, i.e. hepatitis A virus
- 2770/32421 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32422 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32423 . . . . Virus like particles [VLP]
- 2770/32431 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32432 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32433 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32434 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32441 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32442 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32443 . . . . viral genome or elements thereof as genetic vector
- 2770/32444 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32445 . . . . Special targeting system for viral vectors
- 2770/32451 . . . . Methods of production or purification of viral material
- 2770/32452 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32461 . . . . Methods of inactivation or attenuation
- 2770/32462 . . . . by genetic engineering
- 2770/32463 . . . . by chemical treatment
- 2770/32464 . . . . by serial passage
- 2770/32471 . . . . Demonstrated *in vivo* effect
- 2770/32488 . . . . for redistribution
- 2770/32511 . . . . Parechovirus, e.g. human parechovirus
- 2770/32521 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32522 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32523 . . . . Virus like particles [VLP]
- 2770/32531 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32532 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32533 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32534 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32541 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32542 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32543 . . . . viral genome or elements thereof as genetic vector
- 2770/32544 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32545 . . . . Special targeting system for viral vectors
- 2770/32551 . . . . Methods of production or purification of viral material
- 2770/32552 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32561 . . . . Methods of inactivation or attenuation
- 2770/32562 . . . . by genetic engineering
- 2770/32563 . . . . by chemical treatment
- 2770/32564 . . . . by serial passage
- 2770/32571 . . . . Demonstrated *in vivo* effect
- 2770/32588 . . . . for redistribution
- 2770/32611 . . . . Poliovirus
- 2770/32621 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32622 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32623 . . . . Virus like particles [VLP]
- 2770/32631 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32632 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32633 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32634 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32641 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32642 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32643 . . . . viral genome or elements thereof as genetic vector
- 2770/32644 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32645 . . . . Special targeting system for viral vectors
- 2770/32651 . . . . Methods of production or purification of viral material
- 2770/32652 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32661 . . . . Methods of inactivation or attenuation
- 2770/32662 . . . . by genetic engineering
- 2770/32663 . . . . by chemical treatment
- 2770/32664 . . . . by serial passage
- 2770/32671 . . . . Demonstrated *in vivo* effect

- 2770/32688 . . . . for redistribution
- 2770/32711 . . . Rhinovirus
- 2770/32721 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32722 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32723 . . . . Virus like particles [VLP]
- 2770/32731 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32732 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32733 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32734 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32741 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32742 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32743 . . . . . viral genome or elements thereof as genetic vector
- 2770/32744 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32745 . . . . . Special targeting system for viral vectors
- 2770/32751 . . . . Methods of production or purification of viral material
- 2770/32752 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32761 . . . . Methods of inactivation or attenuation
- 2770/32762 . . . . . by genetic engineering
- 2770/32763 . . . . . by chemical treatment
- 2770/32764 . . . . . by serial passage
- 2770/32771 . . . . Demonstrated *in vivo* effect
- 2770/32788 . . . . for redistribution
- 2770/34011 . . Potyviridae
- 2770/34021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/34022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/34023 . . . Virus like particles [VLP]
- 2770/34031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/34032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/34033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/34034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/34041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/34042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/34043 . . . . viral genome or elements thereof as genetic vector
- 2770/34044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/34045 . . . . Special targeting system for viral vectors
- 2770/34051 . . . Methods of production or purification of viral material
- 2770/34052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/34061 . . . Methods of inactivation or attenuation
- 2770/34062 . . . . by genetic engineering
- 2770/34063 . . . . by chemical treatment
- 2770/34064 . . . . by serial passage
- 2770/34071 . . . Demonstrated *in vivo* effect
- 2770/34088 . . . for redistribution
- 2770/36011 . . Togaviridae
- 2770/36021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36023 . . . Virus like particles [VLP]
- 2770/36031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/36042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36043 . . . . viral genome or elements thereof as genetic vector
- 2770/36044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36045 . . . . Special targeting system for viral vectors
- 2770/36051 . . . Methods of production or purification of viral material
- 2770/36052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36061 . . . Methods of inactivation or attenuation
- 2770/36062 . . . . by genetic engineering
- 2770/36063 . . . . by chemical treatment
- 2770/36064 . . . . by serial passage
- 2770/36071 . . . Demonstrated *in vivo* effect
- 2770/36088 . . . for redistribution
- 2770/36111 . . . Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- 2770/36121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36123 . . . . Virus like particles [VLP]
- 2770/36131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2770/36132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36141 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/36142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36143 . . . . . viral genome or elements thereof as genetic vector
- 2770/36144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36145 . . . . . Special targeting system for viral vectors
- 2770/36151 . . . . . Methods of production or purification of viral material
- 2770/36152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36161 . . . . . Methods of inactivation or attenuation
- 2770/36162 . . . . . by genetic engineering
- 2770/36163 . . . . . by chemical treatment
- 2770/36164 . . . . . by serial passage
- 2770/36171 . . . . . Demonstrated *in vivo* effect
- 2770/36188 . . . . . for redistribution
- 2770/36211 . . . . Rubivirus, e.g. rubella virus
- 2770/36221 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36222 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36223 . . . . . Virus like particles [VLP]
- 2770/36231 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36232 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36233 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36234 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36241 . . . . . Use of virus, viral particle or viral elements as a vector
- 2770/36242 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36243 . . . . . . viral genome or elements thereof as genetic vector
- 2770/36244 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36245 . . . . . . Special targeting system for viral vectors
- 2770/36251 . . . . . . Methods of production or purification of viral material
- 2770/36252 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36261 . . . . . . Methods of inactivation or attenuation
- 2770/36262 . . . . . . by genetic engineering
- 2770/36263 . . . . . . by chemical treatment
- 2770/36264 . . . . . . by serial passage
- 2770/36271 . . . . . Demonstrated *in vivo* effect
- 2770/36288 . . . . . for redistribution
- 2770/38011 . . . . . Tombusviridae
- 2770/38021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/38022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/38023 . . . . . Virus like particles [VLP]
- 2770/38031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/38032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/38033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/38034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/38041 . . . . . Use of virus, viral particle or viral elements as a vector
- 2770/38042 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/38043 . . . . . . viral genome or elements thereof as genetic vector
- 2770/38044 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/38045 . . . . . . Special targeting system for viral vectors
- 2770/38051 . . . . . . Methods of production or purification of viral material
- 2770/38052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/38061 . . . . . . Methods of inactivation or attenuation
- 2770/38062 . . . . . . by genetic engineering
- 2770/38063 . . . . . . by chemical treatment
- 2770/38064 . . . . . . by serial passage
- 2770/38071 . . . . . Demonstrated *in vivo* effect
- 2770/38088 . . . . . for redistribution
- 2770/40011 . . . . . Tymoviridae
- 2770/40021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/40022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/40023 . . . . . Virus like particles [VLP]
- 2770/40031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/40032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/40033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/40034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/40041 . . . . . Use of virus, viral particle or viral elements as a vector
- 2770/40042 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/40043 . . . . . . viral genome or elements thereof as genetic vector

- 2770/40044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/40045 . . . . Special targeting system for viral vectors
- 2770/40051 . . . . Methods of production or purification of viral material
- 2770/40052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/40061 . . . . Methods of inactivation or attenuation
- 2770/40062 . . . . by genetic engineering
- 2770/40063 . . . . by chemical treatment
- 2770/40064 . . . . by serial passage
- 2770/40071 . . . . Demonstrated in vivo effect
- 2770/40088 . . . . for redistribution
- 2780/00** **Naked RNA viruses**
- 2780/00011 . . Details
- 2780/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/00023 . . Virus like particles [VLP]
- 2780/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/00041 . . Use of virus, viral particle or viral elements as a vector
- 2780/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/00043 . . . viral genome or elements thereof as genetic vector
- 2780/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/00045 . . . Special targeting system for viral vectors
- 2780/00051 . . Methods of production or purification of viral material
- 2780/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/00061 . . Methods of inactivation or attenuation
- 2780/00062 . . . by genetic engineering
- 2780/00063 . . . by chemical treatment
- 2780/00064 . . . by serial passage
- 2780/00071 . . Demonstrated in vivo effect
- 2780/00088 . . for redistribution
- 2780/10011 . . Narnaviridae
- 2780/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/10023 . . . Virus like particles [VLP]
- 2780/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2780/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/10043 . . . . viral genome or elements thereof as genetic vector
- 2780/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/10045 . . . . Special targeting system for viral vectors
- 2780/10051 . . . . Methods of production or purification of viral material
- 2780/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/10061 . . . . Methods of inactivation or attenuation
- 2780/10062 . . . . by genetic engineering
- 2780/10063 . . . . by chemical treatment
- 2780/10064 . . . . by serial passage
- 2780/10071 . . . . Demonstrated in vivo effect
- 2780/10088 . . . . for redistribution
- 2790/00** **Viroids or subviral agents**
- 2790/00011 . . Details
- 2790/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/00023 . . Virus like particles [VLP]
- 2790/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/00041 . . Use of virus, viral particle or viral elements as a vector
- 2790/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/00043 . . . viral genome or elements thereof as genetic vector
- 2790/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/00045 . . . Special targeting system for viral vectors
- 2790/00051 . . Methods of production or purification of viral material
- 2790/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/00061 . . Methods of inactivation or attenuation
- 2790/00062 . . . by genetic engineering



- 2790/00063 . . . by chemical treatment
- 2790/00064 . . . by serial passage
- 2790/00071 . . Demonstrated in vivo effect
- 2790/00088 . . for redistribution
- 2790/10011 . . Prions
- 2790/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/10023 . . . Virus like particles [VLP]
- 2790/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/10043 . . . . viral genome or elements thereof as genetic vector
- 2790/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/10045 . . . . Special targeting system for viral vectors
- 2790/10051 . . . Methods of production or purification of viral material
- 2790/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/10061 . . . Methods of inactivation or attenuation
- 2790/10062 . . . . by genetic engineering
- 2790/10063 . . . . by chemical treatment
- 2790/10064 . . . . by serial passage
- 2790/10071 . . . Demonstrated in vivo effect
- 2790/10088 . . . for redistribution
- 2790/12011 . . Satellite viruses
- 2790/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/12023 . . . Virus like particles [VLP]
- 2790/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/12042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/12043 . . . . viral genome or elements thereof as genetic vector
- 2790/12044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/12045 . . . . Special targeting system for viral vectors
- 2790/12051 . . . Methods of production or purification of viral material
- 2790/12052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/12061 . . . Methods of inactivation or attenuation
- 2790/12062 . . . . by genetic engineering
- 2790/12063 . . . . by chemical treatment
- 2790/12064 . . . . by serial passage
- 2790/12071 . . . Demonstrated in vivo effect
- 2790/12088 . . . for redistribution
- 2790/14011 . . Viroids
- 2790/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/14023 . . . Virus like particles [VLP]
- 2790/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/14042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/14043 . . . . viral genome or elements thereof as genetic vector
- 2790/14044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/14045 . . . . Special targeting system for viral vectors
- 2790/14051 . . . Methods of production or purification of viral material
- 2790/14052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/14061 . . . Methods of inactivation or attenuation
- 2790/14062 . . . . by genetic engineering
- 2790/14063 . . . . by chemical treatment
- 2790/14064 . . . . by serial passage
- 2790/14071 . . . Demonstrated in vivo effect
- 2790/14088 . . . for redistribution
- 2792/00** **Archaeobacteria viruses**
- 2792/00011 . Details
- 2792/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/00023 . . Virus like particles [VLP]

- 2792/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/00041 . . . Use of virus, viral particle or viral elements as a vector
- 2792/00042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/00043 . . . . viral genome or elements thereof as genetic vector
- 2792/00044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/00045 . . . . Special targeting system for viral vectors
- 2792/00051 . . . Methods of production or purification of viral material
- 2792/00052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/00061 . . . Methods of inactivation or attenuation
- 2792/00062 . . . . by genetic engineering
- 2792/00063 . . . . by chemical treatment
- 2792/00064 . . . . by serial passage
- 2792/00071 . . . Demonstrated in vivo effect
- 2792/00088 . . . for redistribution
- 2792/10011 . . . Fuselloviridae
- 2792/10021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/10022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/10023 . . . . Virus like particles [VLP]
- 2792/10031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/10032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/10033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/10034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/10041 . . . . Use of virus, viral particle or viral elements as a vector
- 2792/10042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/10043 . . . . . viral genome or elements thereof as genetic vector
- 2792/10044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/10045 . . . . . Special targeting system for viral vectors
- 2792/10051 . . . . Methods of production or purification of viral material
- 2792/10052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/10061 . . . . Methods of inactivation or attenuation
- 2792/10062 . . . . . by genetic engineering
- 2792/10063 . . . . . by chemical treatment
- 2792/10064 . . . . . by serial passage
- 2792/10071 . . . . Demonstrated in vivo effect
- 2792/10088 . . . . for redistribution
- 2792/12011 . . . Guttaviridae
- 2792/12021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/12022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/12023 . . . . Virus like particles [VLP]
- 2792/12031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/12032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/12033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/12034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/12041 . . . . Use of virus, viral particle or viral elements as a vector
- 2792/12042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/12043 . . . . . viral genome or elements thereof as genetic vector
- 2792/12044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/12045 . . . . . Special targeting system for viral vectors
- 2792/12051 . . . . Methods of production or purification of viral material
- 2792/12052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/12061 . . . . Methods of inactivation or attenuation
- 2792/12062 . . . . . by genetic engineering
- 2792/12063 . . . . . by chemical treatment
- 2792/12064 . . . . . by serial passage
- 2792/12071 . . . . Demonstrated in vivo effect
- 2792/12088 . . . . for redistribution
- 2795/00 Bacteriophages**
- 2795/00011 . . . Details
- 2795/00021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/00022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/00023 . . . . Virus like particles [VLP]
- 2795/00031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/00032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/00033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/00034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/00041 . . . . Use of virus, viral particle or viral elements as a vector

- 2795/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/00043 . . . viral genome or elements thereof as genetic vector
- 2795/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/00045 . . . Special targeting system for viral vectors
- 2795/00051 . . Methods of production or purification of viral material
- 2795/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/00061 . . Methods of inactivation or attenuation
- 2795/00062 . . . by genetic engineering
- 2795/00063 . . . by chemical treatment
- 2795/00064 . . . by serial passage
- 2795/00071 . . Demonstrated in vivo effect
- 2795/00088 . . for redistribution
- 2795/10011 . . dsDNA Bacteriophages
- 2795/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10023 . . . Virus like particles [VLP]
- 2795/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10043 . . . . viral genome or elements thereof as genetic vector
- 2795/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10045 . . . . Special targeting system for viral vectors
- 2795/10051 . . . Methods of production or purification of viral material
- 2795/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10061 . . . Methods of inactivation or attenuation
- 2795/10062 . . . . by genetic engineering
- 2795/10063 . . . . by chemical treatment
- 2795/10064 . . . . by serial passage
- 2795/10071 . . . Demonstrated in vivo effect
- 2795/10088 . . . for redistribution
- 2795/10111 . . . Myoviridae
- 2795/10121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10123 . . . . Virus like particles [VLP]
- 2795/10131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10141 . . . . Use of virus, viral particle or viral elements as a vector
- 2795/10142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10143 . . . . . viral genome or elements thereof as genetic vector
- 2795/10144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10145 . . . . . Special targeting system for viral vectors
- 2795/10151 . . . . Methods of production or purification of viral material
- 2795/10152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10161 . . . . Methods of inactivation or attenuation
- 2795/10162 . . . . . by genetic engineering
- 2795/10163 . . . . . by chemical treatment
- 2795/10164 . . . . . by serial passage
- 2795/10171 . . . . Demonstrated in vivo effect
- 2795/10188 . . . . for redistribution
- 2795/10211 . . . Podoviridae
- 2795/10221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10223 . . . . Virus like particles [VLP]
- 2795/10231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10241 . . . . Use of virus, viral particle or viral elements as a vector
- 2795/10242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10243 . . . . . viral genome or elements thereof as genetic vector
- 2795/10244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10245 . . . . . Special targeting system for viral vectors
- 2795/10251 . . . . Methods of production or purification of viral material
- 2795/10252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10261 . . . . Methods of inactivation or attenuation

- 2795/10262 . . . . . by genetic engineering
- 2795/10263 . . . . . by chemical treatment
- 2795/10264 . . . . . by serial passage
- 2795/10271 . . . . . Demonstrated in vivo effect
- 2795/10288 . . . . . for redistribution
- 2795/10311 . . . . . Siphoviridae
- 2795/10321 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10322 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10323 . . . . . Virus like particles [VLP]
- 2795/10331 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10332 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10333 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10334 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10341 . . . . . Use of virus, viral particle or viral elements as a vector
- 2795/10342 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10343 . . . . . viral genome or elements thereof as genetic vector
- 2795/10344 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10345 . . . . . Special targeting system for viral vectors
- 2795/10351 . . . . . Methods of production or purification of viral material
- 2795/10352 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10361 . . . . . Methods of inactivation or attenuation
- 2795/10362 . . . . . by genetic engineering
- 2795/10363 . . . . . by chemical treatment
- 2795/10364 . . . . . by serial passage
- 2795/10371 . . . . . Demonstrated in vivo effect
- 2795/10388 . . . . . for redistribution
- 2795/12011 . . . . . dsRNA Bacteriophages
- 2795/12021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/12022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/12023 . . . . . Virus like particles [VLP]
- 2795/12031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/12032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/12033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/12034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/12041 . . . . . Use of virus, viral particle or viral elements as a vector
- 2795/12042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/12043 . . . . . viral genome or elements thereof as genetic vector
- 2795/12044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/12045 . . . . . Special targeting system for viral vectors
- 2795/12051 . . . . . Methods of production or purification of viral material
- 2795/12052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/12061 . . . . . Methods of inactivation or attenuation
- 2795/12062 . . . . . by genetic engineering
- 2795/12063 . . . . . by chemical treatment
- 2795/12064 . . . . . by serial passage
- 2795/12071 . . . . . Demonstrated in vivo effect
- 2795/12088 . . . . . for redistribution
- 2795/14011 . . . . . ssDNA Bacteriophages
- 2795/14021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14023 . . . . . Virus like particles [VLP]
- 2795/14031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14041 . . . . . Use of virus, viral particle or viral elements as a vector
- 2795/14042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14043 . . . . . viral genome or elements thereof as genetic vector
- 2795/14044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14045 . . . . . Special targeting system for viral vectors
- 2795/14051 . . . . . Methods of production or purification of viral material
- 2795/14052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14061 . . . . . Methods of inactivation or attenuation
- 2795/14062 . . . . . by genetic engineering
- 2795/14063 . . . . . by chemical treatment
- 2795/14064 . . . . . by serial passage
- 2795/14071 . . . . . Demonstrated in vivo effect
- 2795/14088 . . . . . for redistribution
- 2795/14111 . . . . . Inoviridae
- 2795/14121 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14122 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14123 . . . . . Virus like particles [VLP]
- 2795/14131 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2795/14132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14141 . . . . Use of virus, viral particle or viral elements as a vector
- 2795/14142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14143 . . . . . viral genome or elements thereof as genetic vector
- 2795/14144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14145 . . . . . Special targeting system for viral vectors
- 2795/14151 . . . . . Methods of production or purification of viral material
- 2795/14152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14161 . . . . . Methods of inactivation or attenuation
- 2795/14162 . . . . . by genetic engineering
- 2795/14163 . . . . . by chemical treatment
- 2795/14164 . . . . . by serial passage
- 2795/14171 . . . . . Demonstrated *in vivo* effect
- 2795/14188 . . . . . for redistribution
- 2795/14211 . . . . . Microviridae
- 2795/14221 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14222 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14223 . . . . . Virus like particles [VLP]
- 2795/14231 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14232 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14233 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14234 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14241 . . . . . Use of virus, viral particle or viral elements as a vector
- 2795/14242 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14243 . . . . . . viral genome or elements thereof as genetic vector
- 2795/14244 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14245 . . . . . . Special targeting system for viral vectors
- 2795/14251 . . . . . . Methods of production or purification of viral material
- 2795/14252 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14261 . . . . . . Methods of inactivation or attenuation
- 2795/14262 . . . . . . by genetic engineering
- 2795/14263 . . . . . . by chemical treatment
- 2795/14264 . . . . . . by serial passage
- 2795/14271 . . . . . Demonstrated *in vivo* effect
- 2795/14288 . . . . . for redistribution
- 2795/16011 . . . . ssRNA Bacteriophages negative-sense
- 2795/16021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/16022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/16023 . . . . Virus like particles [VLP]
- 2795/16031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/16032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/16033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/16034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/16041 . . . . Use of virus, viral particle or viral elements as a vector
- 2795/16042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/16043 . . . . . viral genome or elements thereof as genetic vector
- 2795/16044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/16045 . . . . . Special targeting system for viral vectors
- 2795/16051 . . . . . Methods of production or purification of viral material
- 2795/16052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/16061 . . . . . Methods of inactivation or attenuation
- 2795/16062 . . . . . by genetic engineering
- 2795/16063 . . . . . by chemical treatment
- 2795/16064 . . . . . by serial passage
- 2795/16071 . . . . . Demonstrated *in vivo* effect
- 2795/16088 . . . . . for redistribution
- 2795/18011 . . . . ssRNA Bacteriophages positive-sense
- 2795/18021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/18022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/18023 . . . . Virus like particles [VLP]
- 2795/18031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/18032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/18033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/18034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/18041 . . . . Use of virus, viral particle or viral elements as a vector
- 2795/18042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/18043 . . . . . viral genome or elements thereof as genetic vector

- 2795/18044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/18045 . . . . Special targeting system for viral vectors
- 2795/18051 . . . . Methods of production or purification of viral material
- 2795/18052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/18061 . . . . Methods of inactivation or attenuation
- 2795/18062 . . . . by genetic engineering
- 2795/18063 . . . . by chemical treatment
- 2795/18064 . . . . by serial passage
- 2795/18071 . . . . Demonstrated in vivo effect
- 2795/18088 . . . . for redistribution
- 2795/18111 . . . . Leviviridae
- 2795/18121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/18122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/18123 . . . . Virus like particles [VLP]
- 2795/18131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/18132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/18133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/18134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/18141 . . . . Use of virus, viral particle or viral elements as a vector
- 2795/18142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/18143 . . . . . viral genome or elements thereof as genetic vector
- 2795/18144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/18145 . . . . . Special targeting system for viral vectors
- 2795/18151 . . . . . Methods of production or purification of viral material
- 2795/18152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/18161 . . . . . Methods of inactivation or attenuation
- 2795/18162 . . . . . by genetic engineering
- 2795/18163 . . . . . by chemical treatment
- 2795/18164 . . . . . by serial passage
- 2795/18171 . . . . . Demonstrated in vivo effect
- 2795/18188 . . . . . for redistribution

**2796/00** Viruses not covered by groups  
[C12N 2710/00](#) - [C12N 2795/00](#)

**2799/00** Uses of viruses

**WARNING**

From March 15, 2012 codes in the range [C12N 2799/00](#) - [C12N 2799/06](#) are no longer used for the classification of new documents. The documents in this range are being reclassified to the corresponding codes in [C12N 2710/00-C12N 2795/00](#)

- 2799/02 . . as vector
- 2799/021 . . for the expression of a heterologous nucleic acid
- 2799/022 . . . where the vector is derived from an adenovirus
- 2799/023 . . . where the vector is derived from a poxvirus
- 2799/025 . . . where the vector is derived from a parvovirus
- 2799/026 . . . where the vector is derived from a baculovirus
- 2799/027 . . . where the vector is derived from a retrovirus
- 2799/028 . . . where the vector is derived from a herpesvirus
- 2799/04 . . in vivo
- 2799/06 . . in vitro

**2800/00** Nucleic acids vectors

- 2800/10 . Plasmid DNA
- 2800/101 . . for bacteria
- 2800/102 . . for yeast
- 2800/103 . . for invertebrates
- 2800/105 . . . for insects
- 2800/106 . . for vertebrates
- 2800/107 . . . for mammalian
- 2800/108 . . episomal vectors
- 2800/20 . Pseudochromosomes, minichromosomes
- 2800/202 . . of bacteriophage origin
- 2800/204 . . of bacterial origin, e.g. BAC
- 2800/206 . . of yeast origin, e.g. YAC, 2u
- 2800/208 . . of mammalian origin, e.g. minichromosome
- 2800/22 . Vectors comprising a coding region that has been codon optimised for expression in a respective host
- 2800/24 . Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
- 2800/30 . Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- 2800/40 . Systems of functionally co-operating vectors
- 2800/50 . Vectors for producing vectors
- 2800/60 . Vectors containing traps for, e.g. exons, promoters
- 2800/70 . Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
- 2800/80 . Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- 2800/90 . Vectors containing a transposable element
- 2800/95 . Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
- 2810/00** Vectors comprising a targeting moiety
- 2810/10 . Vectors comprising a non-peptidic targeting moiety
- 2810/40 . Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- 2810/405 . . Vectors comprising RGD peptide
- 2810/50 . Vectors comprising as targeting moiety peptide derived from defined protein
- 2810/55 . . from bacteria
- 2810/60 . . from viruses
- 2810/6009 . . . dsDNA viruses
- 2810/6018 . . . . Adenoviridae

- 2810/6027 . . . ssDNA viruses
- 2810/6036 . . . DNA rev transcr viruses
- 2810/6045 . . . RNA rev transcr viruses
- 2810/6054 . . . . Retroviridae
- 2810/6063 . . . ds RNA viruses
- 2810/6072 . . . negative strand RNA viruses
- 2810/6081 . . . . rhabdoviridae, e.g. VSV
- 2810/609 . . . positive strand RNA viruses
- 2810/65 . . from plants
- 2810/70 . . from fungi
- 2810/75 . . from invertebrates
- 2810/80 . . from vertebrates
- 2810/85 . . . mammalian
- 2810/851 . . . . from growth factors; from growth regulators
- 2810/852 . . . . from cytokines; from lymphokines; from interferons
- 2810/853 . . . . . from tumor necrosis factor, TNF
- 2810/854 . . . . from hormones
- 2810/855 . . . . from receptors; from cell surface antigens; from cell surface determinants
- 2810/856 . . . . . from integrins
- 2810/857 . . . . from blood coagulation or fibrinolysis factors
- 2810/858 . . . . from apolipoproteins
- 2810/859 . . . . from immunoglobulins
- 2810/90 . . . avian
- 2820/00 Vectors comprising a special origin of replication system**
- 2820/002 . inducible or controllable
- 2820/005 . cell-cycle regulated
- 2820/007 . tissue or cell-specific
- 2820/10 . multiple origins of replication
- 2820/55 . from bacteria
- 2820/60 . from viruses
- 2820/65 . from plants
- 2820/70 . from fungi
- 2820/702 . . yeast
- 2820/704 . . . S. cerevisiae
- 2820/706 . . . S. pombe
- 2820/708 . . . C. albicans
- 2820/75 . from invertebrates
- 2820/80 . from vertebrates
- 2820/85 . . mammalian
- 2820/90 . . avian
- 2830/00 Vector systems having a special element relevant for transcription**
- 2830/001 . controllable enhancer/promoter combination
- 2830/002 . . inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- 2830/003 . . . tet inducible
- 2830/005 . . repressible enhancer/promoter combination, e.g. KRAB
- 2830/006 . . . tet repressible
- 2830/007 . cell cycle specific enhancer/promoter combination
- 2830/008 . cell type or tissue specific enhancer/promoter combination
- 2830/15 . chimeric enhancer/promoter combination
- 2830/20 . transcription of more than one cistron
- 2830/205 . . bidirectional
- 2830/30 . being an enhancer not forming part of the promoter region
- 2830/32 . being a silencer not forming part of the promoter region
- 2830/34 . being a transcription initiation element
- 2830/36 . being a transcription termination element
- 2830/38 . being a stuffer
- 2830/40 . being an insulator
- 2830/42 . being an intron or intervening sequence for splicing and/or stability of RNA
- 2830/46 . elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
- 2830/48 . regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- 2830/50 . regulating RNA stability, not being an intron, e.g. poly A signal
- 2830/52 . encoding ribozyme for self-inactivation
- 2830/55 . from bacteria
- 2830/60 . from viruses
- 2830/65 . from plants
- 2830/70 . from fungi
- 2830/702 . . yeast
- 2830/704 . . . S. cerevisiae
- 2830/706 . . . S. pombe
- 2830/708 . . . C. albicans
- 2830/75 . from invertebrates
- 2830/80 . from vertebrates
- 2830/85 . . mammalian
- 2830/90 . . avian
- 2840/00 Vectors comprising a special translation-regulating system**
- 2840/002 . controllable or inducible
- 2840/005 . cell cycle specific
- 2840/007 . cell or tissue specific
- 2840/10 . regulates levels of translation
- 2840/102 . . inhibiting translation
- 2840/105 . . enhancing translation
- 2840/107 . . inhibiting translational read-through
- 2840/20 . translation of more than one cistron
- 2840/203 . . having an IRES
- 2840/206 . . . having multiple IRES
- 2840/44 . being a specific part of the splice mechanism, e.g. donor, acceptor
- 2840/445 . . for trans-splicing, e.g. polypyrimidine tract, branch point splicing
- 2840/50 . utilisation of non-ATG initiation codon
- NOTE**
- This groups covers artificial modification only, i.e. naturally occurring use of non-ATG start codon is not classified here
- 2840/55 . from bacteria
- 2840/60 . from viruses
- 2840/65 . from plants
- 2840/70 . from fungi
- 2840/702 . . yeast
- 2840/704 . . . S. cerevisiae
- 2840/706 . . . S. pombe
- 2840/708 . . . C. albicans
- 2840/75 . from invertebrates
- 2840/80 . from vertebrates
- 2840/85 . . mammalian

2840/90 . . . avian

**2999/00** Further aspects of viruses or vectors not covered by groups [C12N 2710/00](#) - [C12N 2796/00](#) or [C12N 2800/00](#)

**NOTES**

1. This group is for classification of patent and non-patent literature documents.
2. When classifying non-patent literature in this group, classification must also be given for the relevant CPC groups, to define the technical area to which they relate.

2999/002 . Adverse teaching

2999/005 . Biological teaching, e.g. a link between protein and disease, new virus causing pandemic

2999/007 . Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals